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MITOCHONDRIAL TRANSCRIPTION  
FACTOR A’s ROLE IN HEART FAILURE 
George H. Kunkel 
July 14th, 2017 
Background: An essential mitochondrial component, Mitochondrial Transcription 
Factor A (TFAM) is reduced within the failing heart. TFAM maintains regulatory 
functions of cardiomyocyte physiology and stability. Mitochondrial Transcription 
Factor A forms a mitochondrial nucleoid anti-oxidant structure and reduces 
pathophysiological abnormalities to structural and contractile proteins. Overall, this 
functions to physically stabilize mtDNA. Significant molecular changes such as a loss 
of TFAM drive pathophysiological concentrations of cytoplasmic Ca2+ and reactive 
oxygen species. Both of these factors induce proteolytic enzymes to degrade the 
physiological cardiomyocyte. In TFAMs absence, heart function deteriorates and 
hypertrophic expansion ensues: thereby changing the physiological myocardium to a 
pathological state. This alteration activates a remodeling cascade leading to 
cardiomyocyte decline. These maladaptive factors are major players in the 
pathological and time dependent formation of a failing myocardium.  
 Heart failure is a leading cause of death in the United States and a multitude 
of molecular therapeutics individually target Ca2+ transporters or inhibit oxidative 
enzymes. However, the role of TFAM in reducing pathological cardiac remodeling 
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maladaptive factors remains unclear. Furthermore, the purpose of this study is to 
assess TFAM’s role in inhibiting ROS and Ca2+ driven cardiomyocyte remodeling 
factors. 
 
Methods: In the first set of experiments, we studied the effect of TFAM 
overexpression vector and Crispr-cas9 knockdown on HL-1 cardiomyocytes. The 
cells were subjected to oxidative stress through hydrogen peroxide treatment and the 
analysis was compared to a standard control as well as control treatment groups; 
Lipofectamine and an empty vector. Molecular analysis of cardiomyocte remodeling 
factors Calpain1, MMP9 and NFAT4 and Ca2+ transporter SERCA2a was assessed 
via western blotting and immunocytochemistry. Statistical analysis was performed on 
graphpad prism software.  
 
In the second set of experiments, we studied the effects of aortic banding on TFAM 
transgenic mice. Trans-aortic constriction surgery with a 271/2g needle was performed 
on 8-10 week old mice. Prior to surgery, echocardiography ultrasound and blood 
pressure (coda tail cuff method) functional assays were performed and served as a 
baseline for post-surgical assessment. Eight weeks post-banding, ultrasound of aortic 
arch perfusion and turbulence were used to assess banding procedure. Cardiac 
hypertrophy, fibrosis and morphology were assessed via heart weight/body weight 
ratio, Mason Trichrome and Hematoxylin & Eosin Staining respectively. Molecular 
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analysis of cardiac remodeling factors; Calpain1, MMP9, NFAT4 and Ca2+ 
transporter SERCA2a were assessed via western blotting and immunohistochemistry.  
 
Results: In vitro analysis of remodeling factors reveals that TFAM knockdown 
induces significant increases in maladaptive factors MMP9, Calpain1 and NFAT4. In 
HL-1 cardiomyocytes subjected to pathological concentrations of H2O2 (mimicking 
heart failure in vivo studies), TFAM overexpression mitigated hypertrophic stimulator 
and ROS inducer NFAT4 and decreased MMP9 expression. The TFAM transgenic 
animal model has reduced cardiac hypertrophy and morphology when compared to 
it’s WT surgical counterpart. Molecular analysis shows that TFAM overexpression 
reduces ROS propagated proteases (MMP9) and hypertrophic factors (NFAT4) in 
cardiac remodeling. Additionally, it was observed that TFAM overexpression does 
not increase SERCA2a protein expression and Calpain1 remains high in the TFAM-
TG TAC model.  
 
Conclusion: This study reveals that TFAM overexpression plays a vital role in 
pressure overload heart failure by inhibiting NFAT4 and MMP9. The Ca2+ induced 
Calpain1 pathway is not mitigated by TFAM overexpression in the TAC pressure 
overload model, but additional Ca2+ transporters may be affected by TFAM 
overexpression. TFAM loss or overexpression shifts the homeostatic balance held 
within the physiological myocardium. 
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Pumping around 72 times per minute or over 100,000 times per day for the 
average resting adult, the physiological heart is the strongest muscle in the human 
body. The heart's primary function is to enable deoxygenated blood from tissues to 
pick up oxygen from the lungs and return this newly oxygenated blood back to those 
tissues. Tissue oxygenation is dependent on a functional myocardium consisting of 
four working chambers. The first two chambers of the heart, the right atrium and the 
right ventricle, pump blood through the pulmonary circulatory system. After blood 
absorbs oxygen in the lungs, this oxygenated blood then cycles through the left atrium 
and left ventricle and progresses to the tissues via the systemic circulatory system.  
To incessantly force blood to even the most distant extremities, the heart must 
generate a substantial amount of force. However, there are situations in which the 
workload becomes excessive. These situations are detected by medical professionals 
via changes in both perfusion and pressure dynamics. As the workload increases in 
intensity and the heart’s normal capabilities grow inadequate, delivery to tissues 
become limited. To fulfill these new delivery requirements, the heart initiates 







enlargement. This restructuring of the entire heart muscle is denoted as cardiac 
remodeling. In a chronic situation, cardiac remodeling results in a condition in which 
the heart’s ability to meet the body’s demand for blood and oxygen progressively 
declines. One measure of the heart’s ability to pump blood throughout the body is 
ejection fraction. This measure is defined as the percentage of blood leaving the left 
ventricle with each heartbeat. Once this value degenerates below 55%, this 
inefficiency is categorized as heart failure (HF).  
 HF results from a multitude of agents, including cardiovascular diseases 
(CVD). HF produced by CVDs is prevalent across the United States, affecting 5.7 
million Americans, with a high fatality rate five years post onset (Fig. 1). Associated 
risk factors for heart failure include hypertension, obesity, high cholesterol, diabetes, 
and smoking (Shrout, Rudy, and Piascik 2017). Furthermore, a sedentary lifestyle, 
coupled with a lack of exercise, exacerbates the risk of developing heart failure 
(Mozaffarian et al. 2016; Pearson-Stuttard et al. 2017). 
After the onset of heart failure, the body suffers the effects of cardiac 
inefficiency. These effects include edema, weight gain, and shortness of breath. 
Therapeutics such as diuretics, dietary restrictions, and oxygen therapy manage but 
do not ameliorate the progressive nature of heart failure. The root to intrinsically 
changing a pathological myocardium into a more efficient pumping organ remains at 









Factors Influencing Pathological Cardiac Remodeling 
MMPs 
 Heart failure is a multifaceted disease state encompassing a variety of 
significant changes to structural/contractile proteins and the extracellular matrix 
(Hammerling and Gustafsson 2014). The extracellular matrix of cardiomyocytes, or 
the cardiac matrix, serves as a physical scaffolding to support the structural and 
functional integrity of the myocardium. It provides a microenvironment for 
mechanical, cellular, and molecular activities and is crucial to supporting the 
physiological myocardium. MMPs and their respective TIMPs (tissue inhibitors of 
metalloproteinases) regulate matrix degradation, which affects cardiac fibrosis and 
performance (Mishra et al. 2013).  
Cardiac fibrosis is the abnormal thickening of myofibers by increasing 
collagen density within the myocardial tissue. This is caused by increased 
proliferation of cardiac fibroblasts, which induces connective tissue up-regulation. 
Cardiac fibrosis leads to heart failure (Fan et al. 2012). Fibrotic regions within the 
injured myocardium create cardiac stiffening, decreasing ventricular elastance 
(Kawaguchi et al. 2003). The ratio of the two major fibrous macromolecules collagen 
and elastin found within the cardiac matrix affects myocardial force. Cardiac ECM 
collagen/elastin ratio changes in the course of cardiomyopathies such as heart failure, 
during which MMPs are significantly increased.  
In myocardial tissue damage, enhanced oxidative stress leads to remodeling of 







concentrations induce apoptosis, myocyte hypertrophy, and interstitial fibrosis by 
activating matrix metalloproteases (MMPs) (Spinale et al. 1998; Siwik et al. 1999). 
MMPs degrade a wide spectrum of extracellular proteins that lead to remodeling of 
the matrix (Vu and Werb 2000). The degradation of extracellular proteins provides an 
abnormal microenvironment of matrix, in which the myocytes interact. The MMPs 
degrade collagen and elastin in the matrix. In heart failure, collagen is replaced faster 
than elastin, altering the collagen/elastin ratio (Tyagi 1998; Weber et al. 1994; 
Mujumdar, Smiley, and Tyagi 2001). Collagen deposition decreases the tensile 
strength of the ventricular walls, leading to dilated cardiomyopathy.  
 MMPs are zinc-dependent endopeptidases, capable of degrading the 
extracellular matrix (ECM), resulting in cardiac remodeling. This family of proteases 
has two well-studied members within the cardiac system: MMP2 and MMP9 play a 
role in heart failure. This family of proteases is recognized for its involvement in 
cardiac remodeling and atherosclerotic plaque formation. Mittal et al noted two 
genetic polymorphisms involved in the development of coronary artery disease, a 
factor in heart failure (HF) (Mittal et al. 2014). Molecular mechanisms that promote 
anabolic cascades involving MMP 2 & 9 are reduced with increased TIMP expression 
(Frati et al. 2015).  
Polyakova et al. studied collagen metabolism and MMP/TMP activity. 
Analysis of failing human hearts revealed that specific MMPs are associated with 
particular types of heart failure. Although MMP 2 & 9 had increased levels in all 







up-regulation in dilated cardiomyopathies (Polyakova et al. 2011; Chaturvedi et al. 
2015). Conclusively, all forms of heart failure exhibited an increase in collagen 
deposition within the cardiac system, and cardiac fibrosis is noted as a factor in heart 
failure (Polyakova et al. 2011; Polyakova et al. 2004).  
The Tyagi laboratory has demonstrated the significance of MMP9 and TIMP-
3 in cardiac hypertrophy. Attenuation of MMP9 and TIMP3 was observed post-
treatment of mitochondrial division inhibitor (Mdivi), which inhibited cardiac 
mitophagy in the transverse aortic constriction (TAC) pressure overload model. There 
was decreased expression of mitophagy markers, fibrotic deposition, and improved 
echocardiography. The therapeutic activity of Mdivi decreased the proteolytic effects 
of MMP9 by inhibiting abnormal mitophagy, resulting in decreased ROS (Givvimani 
et al. 2012). Future studies of MMP9’s role in the degradative process of heart failure 




Cardiac pathologies involving cardiac hypertrophy and cardiac dilation show 
increased extracellular and intracellular protease activity. Subcellular remodeling of 
the sarcolemma, sarcoplasmic reticulum, myofibrils, and mitochondria occur due to 
proteolytic degradation (Muller et al. 2012). Hemodynamic stress-induced myocardial 
remodeling is caused by increased calpain activity. The Galvez group evaluated 







proteolysis coincided with increased protein ubiquitination and up-regulation of 
protein turnover (Galvez et al. 2007). Stress-induced activation of calpain myocardial 
remodeling occurs via increased Ca2+ concentration, which activates the remodeling 
cascade. Proteases such as calpains molecularly degrade the cellular components of 
cardiomyocytes (Moshal, Metreveli, et al. 2008; Singh et al. 2004).  
Calpains are a family of intracellular cytosolic cysteine proteases activated by 
Ca2+ and localized within the cytosol and mitochondria. The family’s most prevalent 
members are μ-calpain and m-calpain. As heterodimers, the calpain family contains 
two domains: a catalytic (80kda) domain and a regulatory (30kda) domain. Binding 
of Ca2+ to the large subunit induces the activation of the protease function. 
Alternative splicing allows for variations in the calpain protein isoforms, leading to 
five different calpains present in the cardiovascular system: calpain 1, 2, 3, 4, & 5  
(Suzuki et al. 2004b).  
The endogenous inhibitor calpastatin regulates calpain within the myocardium 
to decrease the proteolytic activity in the physiological heart. Calpastatin contains 
four inhibitory domains that bind reversibly to calpain, inhibiting its activity (Suzuki 
et al. 2004a). Calpain inhibitors showing calpistatin-like inhibition significantly 
reduce calpain activity, though in HF excessive calpain expression exceeds the 
counteractivity (Yang et al. 2010; Parameswaran and Sharma 2012). Increased 
calpain levels directly influenced the Angiotensin II (Ang II)/Ang II receptor 
(ATR)/calpain/calpastatin (CaN) pathway, suggesting that protease up-regulation 







also performed by Micro-RNA 181a-3p, which will target the 3’ UTR of calpain 1. 
Exogenous inhibition through micro-RNAs are insufficient in reducing calpain 1 in 
the failing heart (Campos et al. 2014). Analysis of calpastatin deficient mice in 
comparison to wild type revealed a significant reduction in survival rate (Kudo-
Sakamoto et al. 2014).  
An imbalance of proteases and their inhibitors is present within the heart 
failure model (Müller and Dhalla 2012; Wei et al. 2012). Alterations in cytoskeletal 
and contractile proteins due to calpain protease up-regulation causes the degradation 
of proteins such as myosin, F-actin, and titin, resulting in a disorganized sarcomere 
(Ellis et al. 2010). The proteolytic activity of calpains leads to intracellular 
degradation of proteins such as Titin, an essential contractile protein of the sarcomere 
(Kunkel, Chaturvedi, and Tyagi 2015a). 
 Overall, calpains are prevalent in heart failure and cardiac remodeling. The 
protective role of calpain 4’s inhibition was investigated in calpain 4 knockout mice 
subjected to hemodynamic stress by pressure overload, revealing that calpain 4 
deficiency results in decreased calpain 1 & 2 protein levels. Pressure overload via 
TAC caused ventricular dilation, interstitial fibrosis, heart failure, and contractile 
dysfunction (Taneike et al. 2011). Ventricular hypertrophy is correlated with 
increased calpain activity (Takahashi et al. 2005). The literature suggests that overall 
degradation of both contractile and cytoskeletal proteins is mainly caused by calpain 







signaling may occur between regional calpain isoforms, naturally causing a decrease 
in calpain 1 & 2.  
Electrophysiological effects were analyzed during calpain inhibition, 
increasing Ca2+-dependent late Na+ current (INaL) decay. Inhibiting calpain 1 
increased myocyte function/viability and reduced intracellular Ca2+ in primary 
cardiomyocytes (Undrovinas, Maltsev, and Sabbah 2013). Increased calpain 1 & 2 
proteolysis stimulated calcineurin, forming a calmodulin-independent and 
constitutively active calcineurin. Human heart failure patients express calcineurin 
equally in both ventricles. Calcineurin activity was present in micro-Ca2+ 
concentrations, which would increase endogenous calpain expression (Wang et al. 
2012). 
 Therapeutic agents targeting calpain inhibition may be promising to the 
advancement of cardiovascular medicine. The use of calpain inhibitors improve 
cardiomyocyte electrical activity (Undrovinas, Maltsev, and Sabbah 2013).  Current 
therapeutics such as trandolapril and candesartan show that inhibition of calpain 
proteases reduce the rate of cardiomyocyte degradation and ventricular hypertrophy 
in heart failure (Takahashi et al. 2006). Improvement in perfusion and hemodynamics 
is evident post-treatment  (Perrin, Vergely, and Rochette 2004).  Inhibition of the 
calpain protease family is an important factor mitigating molecular dysfunction 
within the progressively failing myocardium. Therapeutics directed towards heart 
failure through calpain activity/expression inhibition may elongate life of heart failure 








Mitigation of cardiomyocyte deterioration depends upon the regulation of 
Ca2+, also known as Ca2+ handling. A major factor in Ca2+ handling within the 
cardiomyocyte is the sarco(endo)plasmic reticulum Ca2+ ATPase 2a (SERCA2a). 
This is an ATP-dependent Ca2+ transporter, responsible for transporting Ca2+ into the 
sarcoplasmic reticulum (SR), while decreasing free Ca2+ in the cytoplasm. When 
down-regulated, excess Ca2+ remains in the cytoplasm, initiating calpain activity.  
SERCA2a is a member of the P type ATPases and serves as an ion-motive 
force in Ca2+ regulation. The SERCA pumps are encoded by a family of three genes: 
SERCA 1, 2 & 3. Alternative splicing of the transcripts derives variations of the gene 
family, and ten known isoforms exist in various tissue groups (Hovnanian 2007). Of 
the cardiomyocyte-specific SERCA family, SERCA2a is the primary isoform 
expressed in cardiac muscle, and it exhibits a cardioprotective function when 
overexpressed. It is observed that SERCA2a over-expression rescues, or inhibits, 
cardiac hypertrophy in rodent HF models (Nakayama et al. 2003; Sakata et al. 2007). 
Additional rudimentary studies in animal models describe the necessary function 
SERCA2a plays in cardiomyopathies.  
SERCA2a knockout (KO) models die of HF after 10 weeks, providing insight 
into its significance (Heinis et al. 2013). Li analyzed the Ca2+ dynamics in these KO 
mice; Ca2+ maintenance was best regulated by increased activity of the Na+-Ca2+ 
exchanger and L-type Ca2+ currents (Li, Louch, et al. 2011). SERCA2a KO mice 







and L-type Ca2+ channels had increased activity in these mice. Loss of SERCA2a 
drives alternative measures to sustain Ca2+ maintenance. Death due to HF occurs after 
10 weeks of SERCA2a KO, showing that the compensatory activity of other 
transporters does not meet the requirements of the cardiomyocyte. Further Ca2+ 
analysis via patch clamp in SERCA2a KO mice reveals a decrease in Ca2+ transient 
amplitudes (Stokke et al. 2010). This finding shows a variation of electrical activity 
found within SERCA2a KO mice. Additionally, SERCA2a activity has been noted to 
suppress cellular alternans found in ventricular arrhythmias (Cutler et al. 2009).  
In HF, the dependency of Ca2+ regulation switches to the Na+/Ca2+ exchanger, 
which is significantly increased in SERCA2a’s absence (Swift et al. 2012). 
CaMKIIδB regulates NCX; it is stated that pharmacological inhibition of CaMKIIδB 
improved cardiac function (Lu et al. 2011; Quijada et al. 2015). Electrical activation 
of the Ca2+ wave is SERCA2a-dependent. It was observed that CAMKII inhibition 
decreased the Ca2+ spark, and CAMKII shift of SR Ca2+ potentiates the Ca2+ wave 
(Stokke et al. 2011; Sikkel et al. 2014). SERCA2a’s absence in heart failure drives 
alternative measures towards naturally ameliorating the Ca2+ issue. This results in 
electrophysiological changes. 
SERCA2a regulation of Ca2+ is crucial to cardiomyocyte stability. Multiple 
laboratories have explored the therapeutic potential of up-regulating SERCA2a in 
cardiomyopathies. SERCA2a is a key protein involved in the sequestration of Ca2+ 
into the SR; importantly, it is reduced in the heart failure model (Sikkel et al.). 







novel therapeutic approach towards reverse-remodeling the injured myocardium 
(Stammers et al. 2015). 
Gene therapy involving SERCA2a up-regulation is a major topic of discussion 
in translational research/clinical medicine (Sikkel et al. 2014; Lipskaia et al. 2010; 
Park and Oh 2013). SERCA2a gene therapy for HF models including acute 
ischemia/reperfusion, chronic pressure overload, and chronic myocardial infarction 
models resulted in a reduction in ventricular arrhythmias (Eltzschig and Eckle 2011). 
Studies show that SERCA2a gene delivery enhanced contractile function and restored 
electrical stability in the heart failure model caused by SR Ca2+ leak (Cutler et al. 
2012). SERCA2a gene transfer reduced Ca2+ leak and ameliorated ventricular 
arrhythmias in HF models (Lyon et al. 2011). Use of adenoviral SERCA2a vectors 
overexpress the SERCA2a protein, causing ameliorating effects in the HF model 
(Lyon et al. 2011; Xin et al. 2011). 
 Phase 1 human clinical gene therapy trials support the in vitro and in vivo 
findings of other investigators, resulting in positive cardiovascular events post-
intracoronary injection of SERCA2a adenovirus vector (Zsebo et al. 2014; Hansen et 
al. 2014). The clinical study of adeno-associated viral vectors (AAV) of SERCA2a 
administration is noted as Ca2+ up-regulation by Percutaneous of Gene Therapy in 
Cardiac Disease (CUPID), focusing on gene therapy treatments for patients with 
advanced heart failure and systolic dysfunction. Viral vectors of SERCA2a show 







as a significant improvement in biochemical alterations, including reduction of 
calpain 1 (Gwathmey, Yerevanian, and Hajjar 2013). 
 Phase 1, or the first 36 months of the trial, exhibited that the SERCA2a AAV 
had significant beneficial clinical effects on the ventricular myocardium (Greenberg 
2015).  Evidence of long term transgene presence, cardiac improvement, and reduced 
worsening of heart failure is found in the clinical trials. Suggesting that a single 
intracoronary treatment of the SERCA2a AAV vector, maintains positive signals in 
patients with advanced heart failure for years (Zsebo et al. 2014). Of four randomized 
clinical trials utilizing SERCA2a gene transfer in heart failure patients, it was 
observed that patients in the high dose group sustained progressive improvements in 
left ventricular function and ejection fraction. Concluding that initial experimental 
analysis of SERCA2a gene transfer in patients is a safe and acceptable approach to 
treating HF (Penny and Hammond 2017). 
In general, scientific literature supports the beneficial aspects of SERCA2a 
gene therapy, as is readily reported (Hayward et al. 2015). Clinical HF trials utilize 
SERCA2a gene therapy as a method of therapeutic repair. In addition to reduction of 
SERCA2a, HF models have reduced mitochondrial function, the Tyagi group and 
others are focused on mitochondrial therapeutics in HF. Mitochondrial transcription 
factor A (TFAM) an essential component of MtDNA is a main regulator of SERCA2a 
gene transcription in cardiomyocytes (Watanabe et al. 2011; Angelini et al. 2015). In 







core of mitochondrial dysfunction. In the failing cardiomyocyte, a lack of 
mitochondrial efficiency drives Ca2+ mishandling and ROS production. 
 Organelles such as the mitochondria and sarcoplasmic reticulum function to 
reduce and store secondary factors like Ca2+, through active transport systems, and 
inhibition of ROS producing enzymes. Mitochondria are the molecular powerhouse 
of cells, shifting the sphere of cardiomyocyte stability and performance. Transcription 
factors like mitochondrial transcription factor A (TFAM) facilitate an essential role in 
cellular regulation through mitochondrial interventions, leading to cardiomyocyte 
protection (Larsson et al. 1998).  
 
Mitochondrial Regulation: Ca2+ & ROS Production 
 An individual’s cardiac health is directly related to the state of their 
mitochondria. The mitochondria plays a significant role in Ca2+ and ROS regulation. 
Ca2+ increases ROS production, which activates degratory proteases and hypertrophic 
factors. Ca2+ and ROS proceed to interact, multiplying one another and worsening the 
condition. Heart failure is a functional lack of myocardial performance that begets 
proteolytic degradation and cardiac remodeling (Quiros, Langer, and Lopez-Otin 
2015). Molecular processes and pathways within cardiomyocytes inhibit the 
underlying components of maladaptive regulation in the physiological cellular 
environment (Val-Blasco et al. 2017). Causes of cardiomyocyte degradation include 







secondary factors activate proteolytic enzymes, resulting in the cardiomyocyte’s 
functional decline. 
Cytoplasmic Ca2+ regulation is imperative to degradative activity within the 
myocardium. Recent reviews depicting the importance of Ca2+ regulation and 
apoptosis unveil the increased Ca2+-driven proteolytic drive found within cell death 
(Orrenius, Gogvadze, and Zhivotovsky 2015; Bhosale et al. 2015; Griffiths, Balaska, 
and Cheng 2010). Excessive Ca2+ mishandling causes intra-mitochondrial 
translocation of calpain 1, affecting mitochondrial bioenergetics. 
Calpains within the mitochondrial matrix contribute immeasurably to 
cardiomyocyte decline. Calpains I, II, & X exist within the mitochondria. Post-(I/R) 
injury, Calpain 1 is up-regulated, which assists in opening the mitochondrial 
permeability transition pore (mPTP) (Shintani-Ishida and Yoshida 2015; Elrod and 
Molkentin 2013). In mitochondrial decline, calpain 1 increases; it cleaves apoptosis 
inducibility factor (AIF), which is then translocated to the nucleus, inducing cell 
death (Cao et al. 2007; Nath et al. 2000; Smith and Schnellmann 2012a). Calpain X is 
a Ca2+-induced mitochondrial protease and a necessity for functional mitochondrial 
activity. Smith observed that both over-expression and deletion of calpain X 
provoked mitochondrial decline. Degradation of mitochondrial calpain X is regulated 
by Lon protease, which is responsible for degrading oxidized proteins within the 
mitochondria in physiological and pathological states. 
The literature has noted that the deficiencies producing ROS lie within the 







mitochondria blocks the electron transport chain at Complex I, inducing ROS 
production. Disrupting the association of Complexes I-III causes a substantial 
increase in ROS from Complex I (Maranzana et al. 2013). The leakage of electrons in 
the electron transport chain produces superoxides. ROS is mainly born of the 
electrons leaking from the mitochondrial complexes of the electron transport chain. 
ROS can further oxidize proteins, resulting in aggregation (Borutaite et al. 2001). In 
cardiomyocytes, cleavage of mitochondrial complexes induces mitochondrial and 
Ca2+-driven autophagy, increasing ROS concentrations to a pathological level. 
The Ca2+/calmodulin/calcineurin-activated pathway and toll-like receptors are 
critical to the activation of T-cells, increase of NFAT, and regulation of ROS 
(Vandewalle et al. 2014). Nuclear factor of activated T-cells (NFAT) is a nuclear 
transcription factor and activator of innate immunity. Our immune systems recognize 
pattern receptors on immune cells like T-cells, macrophages, and neutrophils. This 
initiates NF-kB and mitogen-associated protein kinases (MAPK), which span the 
membrane of immune cells and play a major role in inflammatory activation. A 
necessary component of toll-like receptors’ (TLR) functional activity is its regulation 
by NFAT (Minematsu et al. 2011). Interestingly, prolonged stimulation of TLR-4 
leads to translocation of NFAT into the mitochondria, which reduces ATP production 
(Ma et al. 2015). Calcineurin, a calmodulin-dependent serine/threonine phosphatase, 
is a mechanistic component of NFAT up-regulation. Calmodulin dephosphorylates 
NFAT at the N terminus, causing the translocation of NFAT to the nucleus 







calcineurin allows for NFAT’s transcriptional activation of nuclear encoded genes, 
influencing gene expression (Hogan et al. 2003). The literature states that activation 
of the NFAT pathway directly stimulates pathological hypertrophic genes (Li et al. 
2017). Therefore, NFAT’s inhibition may reduce pathological cardiac hypertrophy. 
Additionally, NFAT regulates the expression of the cardiac-specific ROS-generating 
enzymes NOX 2 & 4 (Williams and Gooch 2014). 
 Mitochondria and NADPH (NOX) enzymes are the leading source of ROS 
involved in cardiac pathology (Sorescu and Griendling 2002). Interestingly, NOX 5 is 
a Ca2+-activated ROS generator and acts in pulsatile fashion. Banfi et al. found that 
Ca2+ activation increases NOX 5 activity, which induces large amounts of ROS 
production. It also acts as a proton channel (Banfi et al. 2001). NOX 5 activity is 
entirely dependent upon intracellular Ca2+ levels and increased phosphorylation of 
NOX 5 sites, resulting in increased Ca2+ sensitivity (Jagnandan et al. 2007). Ca2+ 
activates NFAT, increasing the concentration of superoxides within the cytoplasm of 
cardiomyocytes. 
 Free Ca2+ and excess ROS drive a cardiomyocyte towards eventual failure. 
Regulation of Ca2+ and ROS prevents the progression of HF. Increasing 











Mitochondrial Transcription Factor A (TFAM) 
TFAM Roles and Function 
Mitochondrial dysfunction is correlated with disease states at the core of 
oxidative phosphorylation and energy efficiency, focused on mitochondrial DNA 
(mtDNA). MtDNA is a 16.5 Kd double stranded circular molecule encoding thirteen 
essential components of oxidative phosphorylation. Therefore, since efficient energy 
production is necessary for all basic human processes, mtDNA is vital to the 
restoration of physiological conditions. As noted unanimously in the literature, the 
major regulator of mtDNA copy number in mammalian models is TFAM (Ekstrand et 
al. 2004; Hoppel et al. 2017). The mtDNA copy number is reflective of mtDNA 
transcription and ATP production. TFAM is a promoter-specific enhancer of mtDNA 
and a member of the high-mobility protein group (Larsson et al. 1998; Lyonnais et al. 
2017). This transcription factor is essential for mitochondrial DNA maintenance, 
seeing as it coats mitochondrial DNA, playing a factor in mtDNA stability (Alam et 
al. 2003). TFAM is produced in the nucleus and then transported to the mitochondria. 
TFAM is a major mitochondrial gene-regulator, and, as a transcription factor, it 
modifies gene expression.  
Nuclear regulatory factors including nuclear respiratory factors 1 and 2 (NRF 
1, 2) are upstream regulators of TFAM; this is a link between nuclear activity and 
energy production (Virbasius and Scarpulla 1994; Chouinard et al. 1998). A finding 
through super-resolution microscopy reveals that mitochondrial nucleoids (mtDNA-







2011). TFAM acts as a packaging molecule by storing a single copy of mtDNA in a 
functional mitochondrial nucleoid (Kukat et al. 2015). Mitochondrial nucleoids 
contain essential enzymes of an integral antioxidant system, including manganese 
superoxide dismutase (SOD2) and mitochondrial glutathione peroxidase (GPx1) 
(Kienhofer et al. 2009; Ishihara et al. 2015; Pohjoismaki and Goffart 2017). These 
antioxidant enzymes mitigate oxidative damage and protect mtDNA. Components of 
the nucleoid create a safe environment for functional mtDNA processes such as 
transcription, transduction, and repair (Hensen et al. 2014). The molecular 
components of TFAM are a benefactor to cardiomyocyte cellular functions. 
TFAM transcriptional machinery consists of two high-mobility groups: HSP 
(heavy strand promoter) and LSP (light strand promoter). TFAM allows 
mitochondrial-directed RNA-polymerase (POLRMT) to interact with the DNA 
promoter to initiate transcription and produce the primary transcripts of mRNA, 
rRNA, and tRNA (Falkenberg, Larsson, and Gustafsson 2007). As a major regulator 
of mtDNA transcriptional machinery, TFAM has direct regulation over the minor 
transcription factors TFB1M and TFB2M. These transcription factors directly 
promote transcription, using POLRMT (Falkenberg et al. 2002; Song et al. 2012). 
TFBM1 is a dual-function protein acting as a transcription factor and an RNA 
methyl-transferase enzyme (Seidel-Rogol, McCulloch, and Shadel 2003).  
Aside from indirect gene regulation through TFBM 1&2, TFAM also directly 
regulates promoter regions of DNA by binding to the promoter-specific region, which 







additional function of the TFBM 1&2 is binding single-stranded DNA to stabilize 
unwound promoter regions. There is a strong correlation between TFAM/TFBM 1&2 
expression and initiation of mtDNA replication. Additionally, increased TFAM 
expression reduced neuronal pathologies and increased patient survival rate, deeming 
it clinically beneficial (Correia et al. 2011). A significant component of mitochondrial 
transcription, the mitochondrial RNA polymerase, requires TFAM and TFBM2 for 
efficient initiation (Morozov et al. 2014; St John et al. 2006).  
Mapping the binding sites of TFAM and TFBM2 resulted in novel functional 
aspects of TFBM2 binding. TFAM binding to an upstream promoter region activates 
the pre-initiation complex, which requires the binding of TFB2M for specific contact 
with promoter DNA. Loss of TFBM2 leads to nonspecific contact with DNA. 
Functionally, TFB2M separates the DNA strands and plays a role in initiating 
transcription. TFBM2 can reposition the specificity loop of mtRNAP to recognize 
specific promoters (Morozov et al. 2014; Morozov et al. 2015). Mitochondrial protein 
formation is regulated by mitochondrial ribosomes, consisting of two subunits: the 
small (28S) mitochondrial ribosome subunit and the larger (55S) subunit. Post- the 
regulatory functions of forming the initiation complex, TFB1M regulates the 
assembly of the 28S subunit by acting as a 12S ribosomal RNA methyltransferase. 
Observations have concluded that POLRMT’s activities catalyze TFB1M’s 
methyltransferase function, resulting in protein formation (Surovtseva and Shadel 







It is noted that both of these factors [TFB1M & TFB2M] are cooperative 
downstream effectors for mitochondrial biogenesis. More specifically, TFB2M 
functions to maintain mtDNA transcription. TFB1M’s 12S rRNA methyltransferase 
activity is essential for mitochondrial translation and metabolism. Hypermethylation 
caused by over-expression of TFB1M methyltransferase activity results in cell death 
and abnormal biogenesis (Cotney, McKay, and Shadel 2009; Chen, Yi, and Sun 
2014). To emphasize the importance of the methylation activity of TFB1M, studies 
show the effects of disrupting cardiac TFB1M. Complete loss of adenine di-
methylation of rRNA decreased mitochondrial translation and reduced ribosomal 
function (Metodiev et al. 2009). As noted above, TFAM has direct regulation over 
TFB1M & TFB2M. Ablation of TFAM in neonatal mice led to sufficient decreases in 
the cardiac respiratory chain, affecting mitochondrial biogenesis (Wang et al. 1999; 
Larsson et al. 1998; Schwarz et al. 2014).  
TFAM’s major regulatory activities of mtDNA led to direct regulation over 
mitochondrial gene expression, affecting not only the 13 essential genes required for 
oxidative phosphorylation, but also mitochondrial biogenesis and ATP production. 
Understanding the essence of mitochondrial biogenesis and oxidative phosphorylation 
is the key to cardiovascular pathologies (Vega, Horton, and Kelly 2015). 
Mitochondrial dysfunction within cardiomyocytes can lead to HF, but the core of 
mitochondrial defects is found within the stability of mtDNA. As stated previously, 
TFAM is a DNA-binding protein directly related to mitochondrial stability. Mutant 







on) models, which hampered mtDNA function and stability. Impairment of mtDNA 
via mutUNG1 up-regulation resulted in rapid hypertrophic cardiomyopathy, leading 
to HF and death. This culminated into pathological effects such as reduced mtDNA 
replication & transcription, diminished mt respiration, impaired fission/fusion 
dynamics, and significantly decreased cardiomyocyte contractility (Lauritzen et al. 
2015). It would be interesting to observe the effects of exogenous TFAM 
administration into this mutant model.  
TFAM, one of the many mitochondrial stability factors, manages mechanistic 
components involved in mitochondrial biogenesis. It plays a significant role in 
genetic and epigenetic control over downstream factors. Although it is known that 
TFAM’s primary purpose is to sustain mitochondrial DNA and mitigate mutagenic 
activity by creating an antioxidant environment, many secondary functions are in 
need of further exploration.  
 
TFAM Transport 
TFAM is synthesized in the nucleus and transported to the mitochondria. 
TFAM translocation to the mitochondria for initiation of transcription and translation 
requires the binding of chaperones, which creates a heat shock protein (HSP) 
complex. Deocaris and colleagues describe the intimate interaction between HSP60 
and HSP70 (Deocaris, Kaul, and Wadhwa 2006). Lon protease is an ATP-dependent 
protease with chaperone properties; it promotes the association of heat shock protein 







the HSP60-70 complex upon Lon’s binding to the HSP60 subunit. Loss of Lon leads 
to HSP60 dislocation, protein degradation, and apoptotic signaling activation upon 
HSP60’s binding to the regulator, P53 (Kao et al. 2015).  
Coincidentally, in apoptotic signaling, free HSP-60 binds to the TLR-4 
binding domain of T-cells, increasing NFAT activity. Exogenous HSP-60 binds to 
TLR-4 and induces apoptotic signaling (Kim et al. 2009). Kim et al. assert that this 
may be a mechanism of myocyte loss in HF. Li states that myocardial ischemia 
induces an apoptotic signaling cascade, affirming that HSP-60 increases the 
expression of caspases 3 & 8. In TLR-4 deficient mice (I/R) injury had reduced 
myocardial apoptosis and cytokine expression (Li, Si, et al. 2011). The interplay 
between HSP-60 and TLR-4 is essential to mediating apoptotic signaling within 
cardiovascular diseases. However, the HSP60-70 complex has a positive regulatory 
function within cardiomyocytes. Interestingly, this is NF-kB dependent, due to NF-
kB regulation over NFAT up-regulation (Wei et al. 2015).  
Lon protease’s coupling with TFAM was observed in drosophila Schneider 
cells (Matsushima, Garesse, and Kaguni 2004). The HSP60-70 complex is Lon-
dependent, and, importantly, TFAM binds to the HSP70 component. The interaction 
of TFAM bound to HSP-70 at the nucleus allows for transportation of TFAM into the 
mitochondria (Santos, Mishra, and Kowluru 2014). Lon can be personified as 
TFAM’s personal trainer, keeping TFAM fit for mitochondrial biogenesis. An article 
by Naka and colleagues suggests that HSP70 transgenic mice are cardioprotective in a 







apoptotic signaling by mediating P53, Bax, caspase-3&9, and PARP-1 (Naka et al. 
2014). Up-regulation of HSP-70 will increase mitochondrial biogenesis by increasing 
TFAM transport. This regulates Ca2+, leading to decreased protease activity and 
apoptotic signaling. Santos describes TFAM’s binding to HSP60, but at a lower 
affinity when compared to HSP70 (Santos, Mishra, and Kowluru 2014). TFAM 
transport may be inhibited in high ROS conditions such as cardiomyopathies. 
TFAM’s nuclear and mitochondrial role in sustaining cardiomyocyte function is 
dependent upon inter-organelle transport  
 
TFAM: A Therapeutic Potential 
Mitochondrial transcription factor A (TFAM) creates a mitochondrial 
nucleoid structure around mtDNA, protecting it from mutation, inhibiting NFAT, and 
transcriptionally activating SERCA2a to decrease Ca2+ mishandling. TFAM’s 
regulatory functions over SERCA2a and NFAT contribute to physiological 
cardiomyocyte stability (Kunkel, Chaturvedi, and Tyagi 2016). Current literature 
depicts significant decreases in TFAM as HF progresses. Several clinical studies have 
used gene therapy to up-regulate SERCA2a in heart failure, thereby reducing 
cytosolic Ca2+ and its maladaptive molecular associates (Sikkel et al. 2014; Lyon et 
al. 2011). Therefore, TFAM’s transcriptional activation of SERCA2a should reduce 
Ca2+-activated calpain proteases, while inhibiting ROS production from the Ca2+ 
activated NFAT cascade, which may reduce ROS-driven MMPs. 







therapeutic function. Therefore, with support of past studies, TFAM over-expression 
may increase SERCA2a protein expression, increasing Ca2+ handling into the SR and 
reducing protease activity. Due to Ca2+ up-regulation in the HF model, calpain 
activation is persistent. The literature suggests that continuous calpain up-regulation 
is a major factor in the development of HF (Takahashi et al. 2006; Sonobe et al. 
2014). TFAM up-regulation of SERCA2a will decrease Ca2+ and calpain activity in 
the cytoplasm, reducing structural and contractile degradation.  
TFAM up-regulation and inhibition of NFAT activation would decrease ROS 
production by inhibiting NOX 2&4 activity, thereby reducing MMP 2 & 9 proteolytic 
activities. NOX 4 is significantly increased in HF, and it is an activator of 
cardiomyocyte autophagy. (Sciarretta et al. 2015). Up-regulation of ROS in 
cardiomyocyte autophagy induced the nuclear translocation of calpain 2. Inhibition of 
NOX 4 resisted the translocation of calpain 2 (Chang et al. 2015). Mice with a triple 
KO of NOX 1, 2, and 4 had no effect on NADPH chemo-luminescent signaling in 
cardiac, renal, and aortic tissue samples. Over-expression of NOX 4 greatly increased 
ROS production, inducing MMPs. Oxidative damage decreases TFAM mRNA and 
protein expression, resulting in cardiomyocyte mitochondrial dysfunction (Rezende et 
al. 2015). Anti-oxidant therapeutic lycopene ameliorated ROS production and TFAM 
protein decline, resulting in reduced ventricular remodeling (Yue et al. 2015). 
The lack of TFAM protein expression causes dilated cardiomyopathy with 
reduced mtDNA copy number (Wang et al. 1999). In addition, the reduction of 







al. 2001; Kanazawa et al. 2002; Garnier et al. 2003). The mice in which TFAM is 
overexpressed experience protection from LV remodeling, decreased oxidative stress, 
preserved mtDNA copy number, and mitochondrial function (Ikeuchi et al. 2005). 
Moreover, TFAM over-expression attenuated histopathological changes such as 
interstitial fibrosis, apoptosis, myocyte hypertrophy, and cardiac chamber dilation. In 
TFAM transgenic mice, TFAM over-expression in HF has been reported to increase 
(in a timely manner) the mitochondrial DNA copy number and reverse cardiac tissue 
damage (Russell et al. 2004). Hence, TFAM plays an important role in myocardial 
protection against adverse cardiac remodeling and heart failure. Molecular regulation 
over cardiac remodeling and maladaptive factors is key to preventing myocardial 
decline. 
TFAM regulation over SERCA2a may decrease cytoplasmic Ca2+ levels and 
alleviate calpain activity. Post intramitochondrial translocation of calpain 1, an 
intramitochondrial oxidative burst drives MMP9 activity (Moshal et al. 2006; Casas 
et al. 2003). Calpains are involved in cardiomyocyte necrosis and apoptosis. (Perrin, 
Vergely, and Rochette 2004; Marshall et al. 2014). Both intracellular and 
extracellular proteases perform apoptosis and remodeling in HF. A multitude of 
proteases are found within the cardiovascular system, including calpains, caspases, 
cathepsins, and MMPs. While calpains and caspases remodel the intracellular matrix 
of subcellular organelles, MMPs and cathepsins remodel the extracellular matrix. 
Aligning specific proteases to diseases may lead to future therapeutic advances 







Concluding Statement  
In conclusion, this review seeks to provide a molecular background and 
insight into the holistic abnormal conjuncture of degratory processes involved in heart 
failure and associated cardiomyopathies. As discussed, chaperones transport TFAM 
to the mitochondria. The absence of TFAM in the failing cardiomyocyte contributes 
to cardiomyocyte dysfunction. TFAM over-expression reduces ROS production, 
inhibits NFAT and activates SERCA2a. The extent to which TFAM over-expression 
changes the proteolytic degratory factors in HF is in need of further exploration.  
It is unknown whether TFAM over-expression will mitigate calpain 
proteolytic and NFAT pathological hypertrophic expression post-TAC-induced HF. 
Furthermore, we analyze the effects of TFAM knockdown and over-expression on 
these cardiac remodeling factors. We are the first to examine the effects of aortic 
banding-induced heart failure on TFAM transgenic animals and whether TFAM 
reduces NFAT in stress conditions. Our findings suggest that TFAM has molecular 

























Figure 1. Rate of Heart Failure Attributed Deaths (United States: 2011-2013) 
Fig. 1. The thematic map provided by the Center for Disease Control (CDC) shows the HF death rates from 2011-
2013 for Americans ages 35+. With regards to the state of  Kentucky (KY), the highest rates of HF death are 













Figure 2. Molecular Abnormalities Associated with Cardiomyocyte Decline  
 
Fig. 2. This diagram depicts the known mechanisms for molecular abnormalities involved with cardiomyocyte 
decline. The failing cardiomyocyte contains a multitude of dysregulated factors which induce molecular activity 
leading towards degradation. TFAM’s major function of regulatory activity to inhibit NFAT, reduces pathological 
hypertrophic gene expression and ROS production. Loss of TFAM would result in up-regulation of NFAT and 
blockage of the SERCA2a ATPase pump. This increases cytoplasmic Ca2+ levels inducing protease activity and 
Ca2+ binding calcineurin drives NFAT activation. As an apoptotic trigger, Ca2+ induces the translocation of NF-kB 
resulting in release of the p65 subunit. The p65 subunit binds NFAT greatly stimulating NFAT activity.  This 
mechanistic overview represents the interplay of protease activity, hypertrophic stimulation and the potential 















HYPOTHESIS & SPECIFIC AIMS 
 
 
Key Objective  
 






TFAM over-expression reduces pathological cardiac remodeling and associated 




● Specific Aim #1: To analyze the effect of oxidative stress, TFAM CRISPR 
knockdown and, TFAM over-expression on HL-1 cardiomyocytes. 
● Specific Aim #2: To determine if TFAM over-expression reduces cardiac 
hypertrophy post pressure overload heart failure. 
● Specific Aim #3: To determine if TFAM over-expression reduces proteases 
MMP9, Calpain 1 and cardiac hypertrophic stimulator NFAT4 in pathological 













Figure 3. Proposed Mechanism of TFAM- Mediated Cardiomyocyte Protection 
  
Fig. 3. This diagram describes the hypothesized mechanism for TFAM’s role in cardiomyocyte protection. TFAM 
knockdown is hypothesized to lead to mitochondrial dysfunction and an increase in Ca2+ and ROS-induced 
proteases. TFAM Over-expression is hypothesized to reduce Ca2+-driven Calpain proteases and reduce NFATs, 
ROS production/hypertrophic expression and, thereby reducing MMPs. The former leads to cardiomyocyte 



















TFAM’S MECHANISTIC ROLE IN REMODELING 
 
Introduction: 
       TFAM is a promoter-specific enhancer of mtDNA, regulator of mitochondrial genes and 
mtDNA copy number, and a physical protector of mtDNA (Ekstrand et al. 2004; Kunkel, 
Chaturvedi, and Tyagi 2016). TFAM packages single copies of mtDNA, creating a 
mitochondrial nucleoid (Kukat et al. 2015; Wang et al. 1999). TFAM is transported from the 
nucleus into the mitochondria by chaperone HSP70 (Santos, Mishra, and Kowluru 2014). 
Peroxidase enzymes reside within the nucleoid structure, mitigating oxidative damage to 
mitochondrial DNA (Larsson et al. 1998; Wang et al. 1999; Mandal et al. 2015). TFAM’s 
physical protective function contributes to the mitigation of molecular abnormalities within 
the physiological myocardium, and in pathologies such as heart failure, TFAM is decreased. 
We seek to describe TFAM’s effects on protease/hypertrophic molecular expression when 
influenced by hydrogen peroxide, TFAM over-expression, and CRISPR/Cas9 vector for 
TFAM knockdown. 
        TFAM’s regulatory function to increase SERCA2a transcriptional activity poses insight 
into its therapeutic potential (Watanabe et al. 2011). SERCA2a, an ATP-dependent Ca2+ 







(Kunkel, Chaturvedi, and Tyagi 2015b). SERCA2a knockout models result in Heart Failure; 
SERCA2a activity is significant for cardiomyocyte performance and contains translational 
components (Heinis et al. 2013; Sikkel et al. 2014; Lipskaia et al. 2010; Park and Oh 2013; 
Zsebo et al. 2014). TFAM’s regulation of SERCA2a decreases cytoplasmic Ca2+ levels, 
effectively decreasing protease Calpain 1 expression. Ca2+-driven calpain proteases are 
responsible for the proteolytic degradation of both contractile and cytosolic proteins (Kunkel, 
Chaturvedi, and Tyagi 2015a). Studies show that calpain up-regulation is a major factor in 
cardiomyocyte functional decline (Takahashi et al. 2006). Physical tethering interactions 
between the mitochondria and the sarcoplasmic reticulum play a role in Ca2+ regulation (Li et 
al. 2015; Chen et al. 2012).   
TFAM’s protective function to inhibit NFAT expression reduces cardiomyocyte 
hypertrophy (Fujino et al. 2012). NFAT transcriptionally activates hypertrophic genes. The 
Ca2+-calmodulin-calcineurin cascade plays a role in the activation of T cells and related 
cytokines (Vandewalle et al. 2014). Cytosolic Ca2+ activates the calcineurin/NFAT pathway, 
leading to pathological hypertrophy (Prasad and Inesi 2012). NFAT regulates the expression 
of mitochondrial ROS-generating NADPH Oxidases (NOX), specifically NOX 2&4 
(Williams and Gooch 2014).  Mitochondrial NOX enzymes are a leading source of the ROS 
involved in cardiac pathology (Sorescu and Griendling 2002). TFAM inhibits ROS activator 
NFAT, decreasing MMP9 expression in cardiomyocytes. ROS-driven Matrix-
metalloproteinases (MMPs) are zinc-dependent endopeptidases capable of degrading the 







in cardiac hypertrophy (Givvimani et al. 2012) and described MMP up-regulation in heart 
failure as it pertains to ROS generation (Kunkel, Chaturvedi, and Tyagi 2015b). 
Although MMP 2 & 9 have increased activity in all cardiomyopic states 
(dilated, ischemic and inflammatory), MMP9 has the highest up-regulation in heart 
failure related cardiomyopathies (Romanic et al. 2001). Oxidative stress is evidently 
activating catabolic/proteolytic pathways, such as MMPs, in heart failure models. 
MMP9 is notably up-regulated in pathological conditions of cardiovascular diseases 
(Iyer, Jung, and Lindsey 2016).  In an earlier study, Siwik et al found that hydrogen 
peroxide oxidative stress induced MMP9 activity (Siwik, Pagano, and Colucci 2001). 
We have found that MMP9 triggers the signaling cascade leading to pathological 
cardiac remodeling in human heart end-stage heart failure (Moshal et al. 2005). 
Additionally, we have described the results of MMP9 knockout models and the 
ameliorating effects post AVF induced Heart Failure (Moshal, Rodriguez, et al. 
2008). ROS-induced MMP9 is highly expressed in pathological human hearts 
(Moshal et al. 2005). 
Using CRISPR technology, we analyzed the effects of knocking down TFAM in HL-
1 cardiomyocytes. This study was performed to observe the effects of TFAM vector 
treatments on protease/hypertrophic expression. Studies have shown that neonatal ablation of 
TFAM results in decreased mitochondrial biogenesis and death (Larsson et al. 1998). Down 
regulation of TFAM causes mitochondrial oxidative phosphorylation dysfunction, resulting 







shown the intimate interaction between intramitochondrial translocation of calpain 1, 
resulting in increased oxidative stress and MMP9 expression (Moshal et al. 2006).   
In vivo studies have analyzed the effects of TFAM over-expression, showing 
decreased myocyte hypertrophy, oxidative stress, protease expression, apoptosis, interstitial 
fibrosis, increased mtDNA copy number, and cardiomyocyte stability in myocardial 
infarction/heart failure models (Ikeuchi et al. 2005; Ikeda et al. 2015; Kang, Kim, and 
Hamasaki 2007; Hayashi et al. 2008). Additionally, TFAM protected cells from oxidative 
stress in many in vitro models (Thomas et al. 2012; Xu et al. 2009; Aguirre-Rueda et al. 
2015). Therefore, the purpose of this study is to elucidate TFAM’s role in cardiomyocyte 
stability through protease and hypertrophic regulation. 
 
Materials & Methods 
Chemicals and Antibodies 
     TFAM over-expression and CRISPR vectors were purchased from Genecopia (Rockville, 
Maryland). All primary antibodies were purchased from Abcam (Cambridge, United 
Kingdom). Horseradish peroxidase (HRP)-conjugated secondary antibodies were purchased 
from Santa Cruz Biotechnology (Dallas, Texas, USA). Fluorescent secondary antibodies and 











      The HL-1 Cardiac Muscle Cell line was purchased from EMD Millipore (Darmstadt, 
Germany). Cells were grown in 25 and 75 cm2 flasks using Claycomb Media supplemented 
with 10% FBS, 2 mM L-glutamine, 0.1 mM norepinephrine, and penicillin/streptomycin. The 
medium was changed every 24 hours. Cells were maintained in a 37oC incubator in an 




     Cells were plated in 6-well plates at a count of 600 x 103 cells per well for protein 
isolation. For immunocytochemistry analysis, cells were plated in 8 well chamber slides at 
100 x 103 cells per well. After 24 hours, fresh media was provided prior to treatments.  
 
Abcam primary antibodies used are as follows: Calpain 1 (ab28258), SERCA2 (ab2861),  
NFAT4 (ab83832), TFAM (ab131607) & MMP9 (ab38898) 
Vectors: TFAM Crispr-Cas9 Vector: Genecopia (MCP228370-SG01-1) 
TFAM Over-expression Vector: Genecopia (NM_009360.4) 
 
Transfection of HL-1 Cells with TFAM Vector/ TFAM CRISPR-Cas9 Vector 
     CRISPR/Cas9 knockdown plasmid for TFAM and TFAM over-expression vector were 
transfected into HL-1 cardiomyocytes using the life technologies lipofectamine 2000 reagent. 







Lipofectamine and Opti-MEM and then administered to 6-well plates/chamber slides with 
media lacking pen/strep for 48 hours. Cells were then washed with PBS and harvested for 
western blot analysis. 
 
H2O2 Treatment  
 Hydrogen peroxide was administered to HL-1 cardiomyocytes divided into four 
treatment groups: Control, H2O2, TFAM + H2O2, TFAM. 127 micromolar H2O2 was 
administered to the cells for the last six hours of the 48 hour TFAM vector treatment.  
 
Western Blot Analysis 
          Post- a 48 hour treatment period, HL-1 cell protein was isolated using protein 
extraction buffer (RIPA lysis buffer, protease inhibitor cocktail and PMSF). Wells were 
scraped and the contents transferred to ependorf tubes. Lysates were spun in extraction buffer 
for 12 hours and then centrifuged at 12,000g for 15 min. Supernatant was transferred to new 
tubes and protein concentrations were analyzed via Bradford protein estimation assay. 
Samples were run on a 10/12% sodium dodecylsulfate (SDS)-polyacrylamide gel with Tris-
glycine SDS buffer. The gel was transferred electrophoretically overnight onto a PVDF 
membrane at 4oC. The membrane was blocked with a 5% milk solution for 1 hour. Primary 
antibodies were diluted at a concentration 1:1000 in TBST and incubated on the membrane 
overnight. All membranes were washed in TBST solution 4 times and then incubated with 
secondary HRP conjugated antibody solution for 1 hour at room temperature. Four TBST 







substrate in a BioRad Chemidoc (Hercules, Calif.). Band intensity was determined using 
densitometry analysis. Beta-actin was used to normalize protein loading.  
 
Immunocytochemistry 
           Post-cell treatment, media was aspirated from each well of the eight well chamber 
slide and cells were rinsed with PBS. Cells were fixed at room temperature in 4% 
paraformaldehyde solution for 20 min and washed 3 times with PBS. Blocking was 
performed with a mixed solution of 2% bovine-serum-albumin (BSA) and 0.025% Triton X-
100. Cells were permeabilized for 1 hour. All primary antibodies were incubated in the 
chamber slide at a concentration of 1:100 overnight at 4oC. The wells were aspirated, washed 
3 times and incubated for 90 min with the secondary antibody (1:200) at room temp. The 
chamber slides were washed 3 times more, and DAPI was added at 1:10,000 for 10 min. This 
analysis was observed via Confocal microscopy. 
 
Statistical Analysis 
Data are expressed as means ± SE. Statistical analysis was performed by 
Graphpad Prism software using a one-way ANOVA followed by a Bonferoni 













CRISPR Vector Significantly Increases SERCA2a and Calpain 1 Protein Expression 
To observe the efficacy of the TFAM over-expression vector and the CRISPR-Cas9 
knockdown vector for TFAM, we analyzed TFAM expression with both treatments. Through 
western blotting and confocal analysis, we saw significant decreases in TFAM protein 
expression with the CRISPR vector compared to both the control (p < 0.001) and the TFAM 
over-expression vector (p < 0.001). Additionally, the TFAM over-expression vector showed 
considerable increases in TFAM expression compared to control (p < 0.05) (Fig. 4). 
Western blotting and confocal analysis were used to determine changes in SERCA2a 
expression with both treatments. CRISPR vector significantly increased SERCA2a 
expression in HL-1 cardiomyocytes as compared with the control groups (p < 0.001) (Fig. 5). 
Confocal analysis and western blotting show the CRISPR vector greatly increased Calpain 1 
expression as compared to control groups (p < 0.001) (Fig 7). 
 
CRISPR Vector Significantly Increases NFAT4 and MMP9 Protein Expression 
Western blotting and confocal analysis show that the CRISPR vector significantly 
increased NFAT as compared to control groups. (p < 0.05) (Fig. 6). Comparisons between 
the TFAM vector and CRISPR vector were also notable, showing reduction of NFAT with 
TFAM vector treatment (p < 0.025) (Fig 6). Oxidative Stress observed via DHE staining and 







the CRISPR vector as compared to the control and TFAM vector treatment (p < 0.001, p < 
0.05) (Fig 8) 
 
Hydrogen Peroxide Induced Protease Activity is Attenuated by TFAM Treatment 
H2O2 treatment to HL-1 cardiomyocytes reduced TFAM protein expression (p < 
0.001). Conclusive to our hypothesis, western blotting and confocal analysis show that 
TFAM treatment with H2O2 increased TFAM levels compared to the H2O2 group alone, but 
was still reduced when compared with the control (p < 0.05) (Fig 9). Additionally, Calpain 1 
protein expression increased with ROS-induced stress (p < 0.001). TFAM treatment with 
H2O2 reduced calpain 1 expression when compared to the H2O2 group alone (p < 0.025) but 
still maintained significantly higher Calpain 1 levels than the control (p < 0.05) (Fig 11). 
Western blotting and confocal analysis show that NFAT protein expression was greatly 
increased by H2O2 (p < 0.025). TFAM treatment with H2O2 stress shows a significant 
reduction of NFAT levels in comparison to the H2O2 group alone (p < 0.05), normalizing the 
expression to that of the control. Additionally, there is a significant difference between the 
TFAM + H2O2 group and the TFAM vector (p < 0.05) (Fig 10). Western blotting and 
confocal analysis show that ROS-induced protease MMP9 was significantly increased by 
H2O2 compared to the control (p < 0.001). The TFAM treatment group had decreased MMP9 
expression under ROS stress conditions when compared with the H2O2 group (p < 0.05), but 










Figure 4. CRISPR-Cas9 (TFAM) vector treatment reduces TFAM expression & 
TFAM vector treatment increases TFAM expression 
Fig. 4A. These images (i-v) captured by confocal microscopy and Immunocytochemistry (ICC) provide intra-
cellular visualizations of TFAM within the corresponding experimental groups.  
Fig. 4B. This graph exhibits the fluorescent intensity of TFAM that was provided by the data collected from the 
Image J software. Each fluorescent intensity corresponds to TFAM presence within a specific experimental group. 
With respect to the experimental controls, the intensity of TFAM was significantly greater under the TFAM 
Vector and significantly lower when the CRISPR Vector applied.  
Fig. 4C. This graph displays TFAM proteins expression in HL-1 cardiomyocytes treated with TFAM over-
expression vectors, CRISPR-cas9 vectors and experimental controls. HL-1 cells were treated with 1.0 micrograms 
of vectors for 48 hours before harvesting.  Lysates were analyzed by western blotting for TFAM protein 
expression. With respect to the experimental controls, the protein expression of TFAM was significantly greater 
under the TFAM Vector and significantly lower when the CRISPR Vector applied. The bands were quantified 
using densitometry and the data was graphed for an N of 6 using SEM for significance. Values are expressed as 











Figure 5. CRISPR-Cas9 (TFAM) vector treatment significantly increases 
SERCA2a expression & TFAM vector treatment increases SERCA2a 
expression.  
Fig. 5A. These images (i-v) captured by confocal microscopy and ICC provide intra-cellular visualizations of 
SERCA2a within the corresponding experimental groups.  
Fig. 5B. This graph exhibits the fluorescent intensity of SERCA2a that was provided by the data collected from 
the Image J software. Each fluorescent intensity corresponds to SERCA2a presence within a specific experimental 
group. 
With respect to the experimental controls, the intensity of SERCA2a was the significantly greater under the 
CRISPR Vector and significantly high when the TFAM Vector applied.  
Fig. 5C. This graph displays SERCA2a proteins expression in HL-1 cardiomyocytes treated with TFAM over-
expression vectors, CRISPR-cas9 vectors and experimental controls. HL-1 cells were treated with 1.0 micrograms 
of vectors for 48 hours before harvesting.  Lysates were analyzed by western blotting for SERCA2a protein 
expression. With respect to the experimental controls, the protein expression of SERCA2a was the significantly 
greater under the CRISPR Vector and significantly high when the TFAM Vector applied. The bands were 
quantified using densitometry and the data was graphed for an N of 6 using SEM for significance. Values are 










Figure 6. CRISPR-Cas9 (TFAM) vector treatment increases NFAT4 Expression.  
Fig. 6A. These images (i-v) captured by confocal microscopy and ICC provide intra-cellular visualizations of 
NFAT4 within the corresponding experimental groups.  
Fig. 6B. This graph exhibits the fluorescent intensity of NFAT4 that was provided by the data collected from the 
Image J software. Each fluorescent intensity corresponds to NFAT4 presence within a specific experimental 
group. With respect to the experimental controls, the intensity of NFAT4 was the significantly greater under the 
CRISPR Vector  
Fig. 6C. This graph displays NFAT4 proteins expression in HL-1 cardiomyocytes treated with TFAM over-
expression vectors, CRISPR-cas9 vectors and experimental controls. HL-1 cells were treated with 1.0 micrograms 
of vectors for 48 hours before harvesting.  Lysates were analyzed by western blotting for NFAT4 protein 
expression. With respect to the experimental controls, the protein expression of NFAT4 was the significantly 
greater under the CRISPR Vector. The Bands were quantified using densitometry and the data was graphed for an 












Figure 7. CRISPR-Cas9 (TFAM) vector treatment increases Calpain 1 
expression. 
Fig. 7A. These images (i-v) captured by confocal microscopy and ICC provide intra-cellular visualizations of 
Calpain 1 within the corresponding experimental groups.  
Fig. 7B. This graph exhibits the fluorescent intensity of Calpain 1 that was provided by the data collected from the 
Image J software. Each fluorescent intensity corresponds to Calpain 1 presence within a specific experimental 
group. With respect to the experimental controls, the intensity of Calpain 1 was the significantly greater under the 
CRISPR Vector  
Fig. 7C. This graph displays Calpain 1 proteins expression in HL-1 cardiomyocytes treated with TFAM over-
expression vectors, CRISPR-cas9 vectors and experimental controls. HL-1 cells were treated with 1.0 micrograms 
of vectors for 48 hours before harvesting.  Lysates were analyzed by western blotting for Calpain 1 protein 
expression. With respect to the experimental controls, the protein expression of Calpain 1 was the significantly 
greater under the CRISPR Vector. The bands were quantified using densitometry and the data was graphed for an 










Figure 8. CRISPR-Cas9 (TFAM) vector treatment increases MMP9 Expression.  
Fig. 8A. These dihydroethidium staining images (i-v) captured by confocal microscopy provide intra-cellular 
visualizations of MMP9 within the corresponding experimental groups.  
Fig. 8B. This graph exhibits the fluorescent intensity of MMP9 that was provided by the data collected from the 
Image J software. Each fluorescent intensity corresponds to MMP9 presence within a specific experimental group. 
With respect to the experimental controls, the intensity of MMP9 was the significantly greater under the CRISPR 
Vector  
Fig. 8C. This graph displays MMP9 proteins expression in HL-1 cardiomyocytes treated with TFAM over-
expression vectors, CRISPR-cas9 vectors and experimental controls. HL-1 cells were treated with 1.0 micrograms 
of vectors for 48 hours before harvesting.  Lysates were analyzed by western blotting for MMP9 protein 
expression. With respect to the experimental controls, the protein expression of MMP9 was the significantly 
greater under the CRISPR Vector. The bands were quantified using densitometry and the data was graphed for an 











Figure 9. Hydrogen Peroxide treatment reduces TFAM expression & TFAM 
vector increases TFAM expression.  
Fig. 9A. These images (i-iv) captured by confocal microscopy and ICC provide intra-cellular visualizations of 
TFAM within the corresponding experimental groups.  
Fig. 9B. This graph displays TFAM proteins expression in HL-1 cardiomyocytes treated with a TFAM over-
expression vector, H2O2, a TFAM & H2O2 vector combination and a control. HL-1 cells were treated with 1.0 
micrograms of vectors for 48 hours before harvesting.  Lysates were analyzed by western blotting for TFAM 
protein expression. With respect to the experimental controls, the protein expression of TFAM was the 
significantly greater under the H2O2 Vector. The bands were quantified using densitometry and the data was 
graphed for an N of 6 using SEM for significance. Values are expressed as +/- SEM. N=6. * p < 0.05, ** p<0.025, 
*** p<0.001. 
Fig. 9C. This graph exhibits the fluorescent intensity of TFAM that was provided by the data collected from the 
Image J software. Each fluorescent intensity corresponds to TFAM presence within a specific experimental group. 
With respect to the experimental controls, the intensity of TFAM was the significantly greater under the 










Figure 10. Hydrogen Peroxide treatment increases NFAT4 expression  
Fig. 10A. These images (i-iv) captured by confocal microscopy and ICC provide intra-cellular visualizations of 
NFAT4 within the corresponding experimental groups.  
Fig. 10B. This graph displays NFAT4 proteins expression in HL-1 cardiomyocytes treated with a NFAT4 over-
expression vector, H2O2, a TFAM & H2O2 vector combination and a control. HL-1 cells were treated with 1.0 
micrograms of vectors for 48 hours before harvesting.  Lysates were analyzed by western blotting for NFAT4 
protein expression. With respect to the experimental controls, the protein expression of NFAT4 was the 
significantly greater under the H2O2 Vector. The bands were quantified using densitometry and the data was 
graphed for an N of 6 using SEM for significance. Values are expressed as +/- SEM. N=6. * p < 0.05, ** p<0.025, 
*** p<0.001. 
Fig. 10C. This graph exhibits the fluorescent intensity of NFAT4 that was provided by the data collected from the 
Image J software. Each fluorescent intensity corresponds to NFAT4 presence within a specific experimental 
group. With respect to the experimental controls, the intensity of NFAT4 was the significantly greater under the 









Figure 11. Hydrogen Peroxide treatment increases MMP9 expression and 
Calpain 1 expression. 
Fig. 11A. These images (i-iv) captured by confocal microscopy and ICC provide intra-cellular visualizations of 
MMP9 within the corresponding experimental groups.  
Fig. 11B. This graph displays MMP9 proteins expression in HL-1 cardiomyocytes treated with a MMP9 over-
expression vector, H2O2, a TFAM & H2O2 vector combination and a control. HL-1 cells were treated with 1.0 
micrograms of vectors for 48 hours before harvesting.  Lysates were analyzed by western blotting for MMP9 
protein expression. With respect to the experimental controls, the protein expression of MMP9 was the 
significantly greater under the H2O2 Vector. The bands were quantified using densitometry and the data was 
graphed for an N of 6 using SEM for significance. Values are expressed as +/- SEM. N=6. * p < 0.05, *** 
p<0.001. 
Fig. 11C. This graph exhibits the fluorescent intensity of MMP9 that was provided by the data collected from the 
Image J software. Each fluorescent intensity corresponds to MMP9 presence within a specific experimental group. 
With respect to the experimental controls, the intensity of MMP9 was the significantly greater under the H2O2 
Vector  
Fig. 11D. This graph displays Calpain 1 proteins expression in HL-1 cardiomyocytes treated with a Calpain 1 
over-expression vector, H2O2, a TFAM & H2O2 vector combination and a control.  With respect to the 
experimental controls, the protein expression of Calpain 1 was the significantly greater under the H2O2 Vector. 
The bands were quantified using densitometry and the data was graphed for an N of 6 using SEM for significance. 















TFAM’S PROTECTIVE ROLE 





 Hypertensive heart disease and HF are the leading causes of death in the 
United States (Mozaffarian et al. 2016). HF is characterized by activation of cell 
death pathways and mechanisms of degradation (Givvimani et al. 2014). The 
culmination of Ca2+ mishandling and ROS-driven degradation within cardiomyocytes 
leads to a functional decline of the myocardium and hypertrophic expansion, as is 
observed in the HF models discussed later in this chapter. TFAM’s inhibitory 
function to mitigate molecular abnormalities has previously resulted in 
cardioprotective effects when over-expressed (Kunkel, Chaturvedi, and Tyagi 2016). 
A mechanistic analysis of TFAM’s protective role in pathological cardiac remodeling 
gives further insight into both TFAM’s inhibitory effect on the NFAT-ROS-MMP9 
pathway and regulatory effect on the SERCA2a-Calpain 1 pathway. 
The usage of animal models to study cardiac hypertrophy and HF is vital to 
further elucidation of pathophysiological mechanisms. Rickman et al. developed the 
murine TAC procedure, also known as aortic banding. TAC narrows the transverse 







resultant force required for blood ejection. Increased resistance within this model 
causes a pressure overload, resulting in severe hypertension and heart failure. 
 Calpain 1 is responsible for the degradation of contractile proteins, initiation 
of mitochondrial-driven apoptosis, and decrease of Ca2+ transporters in HF (Patterson 
et al. 2011; Chen et al. 2002; Wanichawan et al. 2014). Heart failure patients exhibit 
marked increases in calpains (Yang et al. 2010). Within the Ca2+-driven catabolic 
pathway, Ca2+ activates and increases the expression of calpain proteases and the 
Ca2+-calcineurin-NFAT cascade that promotes pathological hypertrophy and activates 
NADPH oxidases to increase ROS production (Williams and Gooch 2014). 
NFAT is a pathological hypertrophic gene regulator and inducer of ROS via 
activation of NADPH oxidases (Chang et al. 2016; Williams and Gooch 2014). 
NFAT increases in cardiac remodeling and hypertrophy (Houser and Molkentin 
2008). Cytoplasmic Ca2+ increases maladaptive factors NFAT4 and calpain 1.  
 MMP9 is a known pathological indicator of HF, and its expression is highly 
up-regulated in the pathological myocardium (Mujumdar, Smiley, and Tyagi 2001). 
In alignment with this logic, the erasure of MMP9 evokes opposite effects: targeted 
deletion of MMP9 prevents cardiac dysfunction (Prathipati et al. 2016). Inhibitors of 
MMP9 are reduced in heart failure, allowing for MMP9 propagation (Chaturvedi and 
Tyagi 2016). Early-stage aortic banding results in inhibition of MMP9, but sustained 
mechanical overload causes de-compensatory heart failure, leading to increased 
MMP9 expression and cardiac fibrosis in end-stage heart failure.  As aforementioned, 







resulting in increased apoptotic signaling in pressure overload heart failure (Mishra et 
al. 2013). Mitochondrial dysfunction induces ROS production, activating MMPs in 
cardiomyocytes. Superoxides create stress, potentially mutating and damaging 
mitochondrial DNA. 
 TFAM physically wraps around mitochondrial DNA, forming a mitochondrial 
nucleoid; it is essential to mitochondrial biogenesis. One transcriptional function of 
TFAM is regulation over factors such as NFAT and SERCA2a, which provides 
insight into reducing Ca2+ mishandling and ROS production (Watanabe et al. 2011; 
Fujino et al. 2012). Within TFAM over-expression models, it is observed that 
proteolytic enzyme MMP9 is reduced in MI-induced HF, along with functional 
morphologies (Ikeuchi et al. 2005). Contrastingly, our previous study shows that 
CRISPR-CAS9 knockdown of TFAM induces the activation of proteases MMP9 and 
Calpain 1, as well as pathological hypertrophic stimulator and ROS-producer NFAT4 
(Kunkel et al. 2017). 
 The purpose of this study is to investigate the role of TFAM over-expression 
in cardiac remodeling within the TAC HF model. We hypothesized that TFAM over-
expression would reduce molecular remodeling factors and associated morphologies. 
We examined whether TFAM over-expression would reduce molecular hypertrophic 
and proteolytic factors involved in adverse remodeling. Our results affirm that TFAM 









Materials and Methods 
 
 
Animal Models & Experimental Design 
 
Wild type mice (WT, C57/BL6/J) were purchased from the Jackson 
Laboratory (Bar Harbor, ME). TFAM transgenic mice were procured from Cyagen 
Biosciences (Santa Clara, CA,USA) and housed in the animal care facility at the 
University of Louisville with access to standard chow and water. The aortic banding 
surgical procedure was performed in mice of 8-10 weeks of age with starting weights 
of 22-26 grams. The groups were further divided into Control Sham, Control TAC, 
TFAM Sham and TFAM TAC. Animals were euthanized according to National 
Institute of Health Guidelines for animal research and were reviewed and approved 
by the Institute of Animal Care and use committee of the University of Louisville 





The TFAM transgenic mice background was confirmed according to the 
Cyagen Bioscience protocol for genotyping. Samples from the tails of the mice were 
collected for DNA extraction. DNA was amplified with TFAM Primer sets and run 
on PCR. The PCR product samples were run on a 1.2% agarose gel containing 
[Acetic Acid, Tris Base, EDTA, pH 8.4] with ethidium bromide. Gel images were 







transgenic TFAM gene yields a product size of 363 bp in a 2% agarose gel and is 
observed in the BioRad ChemiDoc. 
 
 
Antibodies and Reagents 
 
All primary antibodies were purchased from Abcam (Cambridge, United 
Kingdom). Horseradish peroxidase (HRP)-conjugated secondary antibodies were 
purchased from Santa Cruz Biotechnology (Dallas, Texas, USA). Fluorescent 
secondary antibodies and lipofectamine 2000 reagent was purchased from Life 
Technologies (Carlsbad, California, USA). 
 
Western Blot Analysis 
Post- a 48-hour treatment period, HL-1 cell protein was isolated using protein 
extraction buffer (RIPA lysis buffer, protease inhibitor cocktail and PMSF). Wells were 
scraped and the contents transferred to ependorf tubes. Lysates were spun in extraction buffer 
for 12 hours and then centrifuged at 12,000g for 15 min. Supernatant was transferred to new 
tubes and protein concentrations were analyzed via Bradford protein estimation assay. 
Samples were run on a 10/12% sodium dodecylsulfate (SDS)-polyacrylamide gel with Tris-
glycine SDS buffer. The gel was transferred electrophoretically overnight onto a PVDF 
membrane at 4oC. The membrane was blocked with a 5% milk solution for 1 hour. Primary 
antibodies were diluted at a concentration 1:1000 in TBST and incubated on the membrane 







secondary HRP conjugated antibody solution for 1 hour at room temperature. Four TBST 
washing steps followed before membranes were developed using a chemiluminescent 
substrate in a BioRad Chemidoc (Hercules, Calif.). Band intensity was determined using 
densitometry analysis. Beta-actin was used to normalize protein loading. 
 
Immunohistochemistry 
Post- cell treatment, media was aspirated from each well of the eight well chamber 
slide and cells were rinsed with PBS. Cells were fixed at room temperature in 4% 
paraformaldehyde solution for 20 min and washed 3 times with PBS. Blocking was 
performed with a mixed solution of 2% bovine-serum-albumin (BSA) and 0.025% Triton X-
100. Cells were permeabilized for 1 hour. All primary antibodies were incubated in the 
chamber slide at a concentration of 1:100 overnight at 4oC. The wells were aspirated, washed 
3 times and incubated for 90 min with the secondary antibody (1:200) at room temp. The 
chamber slides were washed 3 times more, and DAPI was added at 1:10,000 for 10 min. This 




Non-invasive tail cuff method was used to measure blood pressure in 
conscious mice (CODA, Kent Scientific, Torrington CT). Animals were allowed time 
to acclimate to chambers and warming pad prior to data recordings. BP was recorded 









 Through Vevo 2100 imaging system, cardiac and aortic data was collected in pre-
surgical and post-surgical animal models. Post epilation the animal is placed supine on a 
warm platform (37oC), under isoflourane anesthesia and fixed. Using a MS550D (22-25 
mHz) transducer, the thoracic cavity was imaged. Aortic arch velocity and cardiographic 
function were assessed in pulse wave and color Doppler modes.   
 
Cryosectioning 
        Cardiac tissue was preserved in plastic tissue embedding molds (polysciences) 
containing tissue freezing media (Triangle Biosciences, Durham, NC). Tissues were stored at 
-80oC. Sections of 8μm were created using a cryocut (leica CM 1850). Cryosections were 




To measure the deposition of collagen within the myocardium, tissue sections were 
stained with a Masson’s Trichrome kit following all manufacturer’s instructions. Collagen 
deposition is represented as a blue color. Images were captured with a light microscope 
(Olympus Fluoview1000). Additionally, sections were stained with Hemotoxylin - Eosin 










Data are expressed as means ± SE. Statistical analysis was performed by 
Graphpad Prism software using a one-way ANOVA followed by a Bonferoni 











































Verification of Aortic Banding Procedure 
 
Through genotyping PCR we confirmed Cyagen Biosciences TFAM 
transgenic mouse protocol to ensure pups are genetically modified with TFAM over-
expression. TFAM gene is overexpressed at 363 base pairs (Fig 12). The aortic 
banding procedure is verified via ultrasound, at which high aortic arch velocity, as 
well as turbulence, is seen at the transverse aorta, comparing WT & TFAM sham 
groups to the aortic banded counterpart (p < 0.001) (Fig 14). Pictographic 
representation of resultant outcome post banding (Fig 13)  
Effect of Aortic Banding on Cardiac Function 
 
TFAM Over-expression Reduced Cardiac Hypertrophy 
 Figure 17A shows a pictographic image of C57 and TFAM-TG mice 
subjected to aortic banding and visually comparing the hearts. This image shows a 
significant visual difference is found when comparing the TAC and sham groups and 
the C57 TAC to the TFAM-TG TAC model. Heart weight is significantly increased in 
the C57 TAC group compared to the C57 sham, TFAM sham and TFAM TAC group 
(Fig. 17B). The heart weight/body weight (Hw/Bw) ration was also significantly 
increased in both the C57 TAC and TFAM TAC groups. The C57 TAC group had 
significantly increased Hw/Bw ratio when compared to the C57 sham, TFAM sham 







banded animals. The C57 TAC gained approximately 2 grams more than the sham 
group and 1 gram more than the TFAM-TAC group (Fig. 17D).  
 
Analysis of Echocardiography and Blood Pressure Results  
Echocardiography and blood pressure analysis show significant differences 
between the aortic banded and sham animals. Ejection fraction (EF) of both TFAM-
TG and WT banded groups showed a significant reduction in comparison to 
respective shams (Fig 15). Changes in LV mass post banding were also observed, 
significantly increased LV mass was found within the C57 TAC & TFAM TAC 
groups when compared to the Sham groups. Additionally, a significant increase in LV 
mass was found in the C57 TAC group when compared to the TFAM TAC group. 
Cardiac muscle hypertrophy is a compensatory response to pressure overload (Fig. 
15). Within the table (Table.1), we observe that many significant functional changes 
occur during pressure overload heart failure, as is observed when comparing the 
Sham and TAC groups. Functional differences are also observed between the WT 
surgical model and the TFAM-TG model, such differences include increased 
fractional shortening, LV volume in systole, LV Mass, LV volume in systole had a 
significant increase in volume in the C57 TAC compared to the C57 sham (Table. 1). 
Variations exist between the TFAM transgenic and its wildtype counterpart 
suggesting that known and unknown mechanisms of mitochondrial protection are 







         The Physiological functional assessment of hemodynamic blood pressure 
measurements was observed at three-time points: 0, 4, 8 weeks, via CODA tail cuff 
blood pressure system. Time point 0 was a pre-surgical assessment and is used as a 
baseline. At 4 weeks, severe hypertension is observed in both TAC groups and is 
significantly higher than the sham group (Fig. 16). Between four weeks and eight 
weeks the C57 group maintains a trending decline in systolic blood pressure, this 
functional change is associated with cardiac remodeling allowing for the heart to 
adapt to the pressure overload through hypertrophic expansion (Fig. 16A). The 
TFAM TAC group maintains a higher systolic blood pressure than the C57 TAC 
group in the four to eight-week time point, therefore a functional difference remains 
between the C57 and TFAM TAC animals. Diastolic blood pressure was assessed and 
revealed a significant difference between the C57 TAC and TFAM TAC groups and 
their sham counterparts at both 4 and 8-week time points (Fig. 16B). Mean blood 
pressure assessment showed a significant difference between the C57 TAC and 
TFAM TAC groups and their sham counterparts (Fig. 16C).  
 
TFAM Over-expression Reduced Histopathologies in HF Mice  
Hemotoxylin & Eosin Staining (H&E), pink color represents myofibers, 
Purple color is Nuclei. In the C57 TAC we observed misplaced/off centered nuclei 
and a dysregulated arrangement of cardiac myofibers, as well as a deformation in size 
and shape. Additionally, an inflammatory response is observed within the WT TAC 







disarrayed pattern compared to all other groups. The TFAM-TG group subjected to 
banding shows a deformation of cardiac myofibers but is not as significant as the WT 
TAC group (Fig. 18A).  
Through mason trichrome staining we observed histopathologies involved in 
HF. Muscle is red and collagen is blue. Comparisons between the C57 TAC group 
and the C57 Sham show a significant increase in collagen in the TAC model. This 
major significance was not observed when comparing the TFAM-TG and its Sham 
counterpart (Fig. 18B). 
 
The Effect of TFAM Over-expression on the NFAT-ROS-MMP9 Pathway 
 
TFAM efficacy in transgenic models was confirmed via western blotting and 
immunohistochemistry for TFAM. Fluorescent intensity was observed via confocal 
microscopy (Fig. 19A). Concluding that the TFAM sham had significantly increased 
TFAM fluorescent intensity (Fig. 19B). Western blotting confirmed a significant 
increase in TFAM protein expression in both TFAM sham and TFAM TAC models. 
There was a significant decrease in TFAM protein expression in the C57 TAC model 
(Fig. 19C).  
Determining if TFAM overexpression affected NFAT4, we observe NFAT4 
fluorescent intensity and Western blotting. The C57 TAC group had significantly 
increased NFAT4 expression compared to all groups (Fig. 20A & B). The TFAM 
TAC group had significantly higher NFAT4 protein expression in comparison to its 







fluorescent intensity is increased in the C57 TAC model in comparison to the C57 
sham, TFAM sham and TFAM TAC (Fig. 21A &B). Western blotting analysis 
revealed a significant increase in MMP9 protein expression (Fig. 21C). TFAM 
overexpression plays a role in the NFAT-ROS-MMP9 pathway. 
 
The Effect of TFAM Over-expression on The SERCA2a-Calpain1 Pathway. 
 
 Analysis of protein expression from cardiac tissue of mice subjected to aortic 
banding and sham controls show that SERCA2a is significantly decreased in pressure 
overload HF. Through Western blotting and immunohistochemistry, the SERCA2a-
Calpain1 pathway was observed for protein and fluorescent expression. Fluorescent 
intensity was viewed via confocal microscopy. Both aortic banded groups C57 & 
TFAM-TG had significantly decreased SERCA2a expression. This was observed in 
western blotting and IHC (Fig.23 A, B&C). 
 Analyzing if TFAM overexpression affected calpain1, we observed calpain1 
fluorescent intensity and protein expression. The C57 TAC and TFAM-TG group had 
significantly increased calpain1 protein expression as observed through western 
blotting. Fluorescent intensity was also as equally increased in IHC. TFAM may play 
a role in physiological SERCA2a expression but this activity is not observed in our 


























Figure 12. Genotyping PCR for TFAM Gene in TFAM and C57 (WT) Mice  
Fig. 12. Genotyping for TFAM gene in TFAM transgenic and C57BLJ6 mice. As per Cyagen Biosciences 

































Figure 13. Effect of Pressure Overload on Myocardium  
Fig. 13. Pictographic representation of the transformation of the myocardium from a pre-surgical heart to a 
pressure overload aortic banding model, 8 weeks post-surgery. Cardiac remodeling and hypertrophic factors 


















Figure 14. Aortic Banding significantly increased Aortic Arch Velocity (AAV). 
Fig. 14A. The top, an ultrasound-echocardiographic snapshot, displays blood flow through the aorta of a particular 
pre-surgical mouse performed with a Vevo 2100 ultrasound pulse wave and color doppler analysis. As indicated 
by the blue coloration, the blood flow is rhythmically non-turbulent. Below, the respective real-time graph of 
AAV versus time displays a consistent AAV average value of 636.14 mm/s.  
Fig. 14B. The ultrasound-echocardiographic snapshot shows blood flow through the aorta performed with a Vevo 
2100 ultrasound pulse wave and color doppler analysis. As indicated by the blue-red-yellow amalgamation, the 
blood flow is rhythmically turbulent. The respective real-time graph of AAV versus time displays an increased 
AAV average value of 1184.10 mm/s from its pre-surgical value seen in 14A.  
Fig. 14C. This graph displays the AAV corresponding to the specified experimental groups and the data was 
graphed for an N of 6 using SEM for significance. The substantial increase in aortic velocity from C57 Sham 
group to the C57 TAC group and the substantial increase from TFAM Sham group to the TFAM TAC group 











Figure 15. Reduced Ejection Fraction (EF) and increased Left Ventricular LV 
Mass in HF.  
Fig. 15A. These images (i-iv) captured by echocardiographic-ultrasound corresponding to the specified 
experimental groups and data taken after 8 weeks. The specified values taken from these images correspond to the 
values discussed in Table 1.  
Fig. 15B. This graph displays the EF corresponding to the specified experimental groups and the data was taken 
after 8 weeks. The significant decrease in EF from C57 Sham group to the C57 TAC group and the significant 
decrease from TFAM Sham group to the TFAM TAC group verify that the aortic banding induced HF. Values are 
expressed for an N of 6 using SEM for significance as +/- SEM. N=6. * p < 0.05, ** p < 0.025, *** p<0.001. 
Fig. 15C. This graph displays the LV mass corresponding to the specified experimental groups and the data was 
taken after 8 weeks. The significant increase in LV mass from C57 Sham group to the C57 TAC group and the 
significant increase from TFAM Sham group to the TFAM TAC group verify that the aortic banding induced HF. 





























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 16. Increased Systolic and Diastolic Blood Pressure Post Banding.  
Fig. 16A. This graph displays the Systolic Blood Pressure measured by the CODA (Tail-cuff) blood pressure 
system. The values correspond to the specified experimental groups throughout the course of 8 weeks. The 
significant decline occurs after 4 weeks. Values are expressed as +/- SEM. N=5; * p < 0.05, ** p < 0.025, *** 
p<0.001. 
Fig. 16B. This graph displays the Diastolic Blood Pressure measured by the CODA (Tail-cuff) blood pressure 
system. The values correspond to the specified experimental groups throughout the course of 8 weeks. The 
significant decline occurs after 4 weeks.  Values are expressed as +/- SEM. N=5; * p < 0.05, ** p < 0.025, *** 
p<0.001. 
Fig. 16C. This graph displays the Mean Blood Pressure measured by the CODA (Tail-cuff) blood pressure system. 
The values correspond to the specified experimental groups throughout the course of 8 weeks. The significant 
















Figure 17. TFAM Over-expression Reduced Cardiac Hypertrophy.  
Fig. 17A. The image displays the cardiac hypertrophy state after 8 weeks correlating to the respective 
experimental groups.  Using visual confirmation, significantly enlarged WT heart due to aortic banding surgical 
procedure was observed when compared to the sham.  Additionally, TFAM-TG reduced hypertrophic 
expansion compared to the TFAM-TG control.  
Fig. 17B. This graph displays heart mass as assessed by micro-calibrated weight scale. The values correspond to 
the specified experimental groups after the course of 8 weeks. The TFAM TAC heart maintained a significantly 
lower mass when compared to the C57 TAC.  
Fig. 17C. This graph depicts the heart weight to body weight ratio that correspond to the specified experimental 
groups after the course of 8 weeks. The TFAM TAC heart maintained a significantly lower ratio when compared 
to the C57 TAC.  
Fig. 17D. This graph shows overall weight gain of the corresponding to the specified groups after the course of 8 
weeks. This was performed by deducting the initial and final mouse weights allowed for an assessment of weight 
gain and variation among controls and transgenic animals. Furthermore, the TFAM TAC mice maintained a 
significantly lower mass weight gain compared to the C57 TAC mice.   












Figure 18. TFAM Reduced Histopathologies in HF. 
Fig. 18A. Histology staining using Haematoxylin & Eosin Stain and  observed via confocal microscopy (i-iv) 
provide a histopathology analysis of the effects of aortic banding on the myocardium. TFAM overexpression 
reduced cardiac remodeling (Fibrosis, Hypertrophy and Inflammation) in vivo. Representative cardiac cross 
sections of Sham and TAC animals sliced at the mid-ventricle level of WT and TFAM-TG mice hearts. 
Pictomicrograph sections in (i) C57 Sham, (ii) C57 TAC, (iii) TFAM Sham, (iiii) TFAM TAC. Hematoxylin and 
Eosin staining for histopathology. Dark pink is muscle and purple is nuclei. Magnification of 60x. Significant 
histopathology in the C57 TAC group. 
Fig. 18B. Histology staining for collagen intensity. Mason Trichrome Staining for collagen intensity (i – v). (i) 
C57 Sham, (ii) C57 TAC, (iii) TFAM Sham, (iv) TFAM TAC; collagen is stained blue and muscle red. 
Magnification of 20x. Significant collagen intensity in the C57 TAC 














Figure 19. TFAM-TG Mice Maintained TFAM Expression in HF.  
Fig. 19A. These confocal microscopy and ICC images (i-iv) provide intra-cellular visualizations of TFAM within 
the corresponding experimental groups. TFAM is identified in green fluorescence and nuclei are identified by blue 
fluorescence.  
Fig. 19B. This graph exhibits the fluorescent intensity of TFAM 8-weeks after TAC and was provided by the data 
collected from the Image J software. Each fluorescent intensity corresponds to TFAM’s presence within the 
specific experimental groups. With respect to TFAM fluorescent intensity, the TFAM overexpression Sham group 
was significantly greater relative to the C57 Sham group.  Also, the TFAM TAC group was shown to be 
significantly greater in intensity of TFAM relative to the C57 TAC group.  
Fig. 19C. This graph displays TFAM proteins expression 8 weeks after the aortic banding surgery. Lysates were 
analyzed by western blotting for TFAM protein expression. The TFAM overexpression Sham group was 
significantly greater in protein expression of TFAM relative to the C57 Sham group. The TFAM overexpression 
TAC group was significantly greater in protein expression of TFAM relative to the C57 TAC group. Both TAC 
groups were significantly decreased in TFAM protein expression when compared to their Sham counterparts.  The 
bands were quantified using densitometry and the data was graphed for an N of 5 using SEM for significance. 














Figure 20. TFAM-TG Mice Decreased NFAT4 Expression in HF. 
Fig. 20A. These confocal microscopy and ICC images (i-iv) provide intra-cellular visualizations of NFAT4 within 
the corresponding experimental groups. TFAM is identified in green fluorescence and nuclei are identified by blue 
fluorescence.  
Fig. 20B. This graph exhibits the fluorescent intensity of NFAT4 8-weeks after TAC and was provided by the data 
collected from the Image J software. Each fluorescent intensity corresponds to NFAT4’s presence within the 
specific experimental groups. With respect to NFAT4 fluorescent intensity, the TFAM TAC group was shown to 
be significantly lower in intensity of NFAT4 relative to the C57 TAC group.  
Fig. 20C. This graph displays NFAT4 proteins expression 8 weeks after the aortic banding surgery. Lysates were 
analyzed by western blotting for NFAT4 protein expression. The TFAM overexpression TAC group was 
significantly lower in protein expression of NFAT4 relative to the C57 TAC group. Both TAC groups were 
significantly increased in NFAT4 protein expression when compared to their Sham counterparts.  The bands were 
quantified using densitometry and the data was graphed for an N of 5 using SEM for significance. Values are 













Figure 21. TFAM-TG Mice Decreased MMP9 Expression in HF. 
Fig. 21A. These confocal microscopy and ICC images (i-iv) provide intra-cellular visualizations of MMP9 within 
the corresponding experimental groups. MMP9 is identified in green fluorescence and nuclei are identified by blue 
fluorescence.  
Fig. 21B. This graph exhibits the fluorescent intensity of MMP9 8-weeks after TAC and was provided by the data 
collected from the Image J software. Each fluorescent intensity corresponds to MMP9’s presence within the 
specific experimental groups. With respect to MMP9 fluorescent intensity, the TFAM TAC group was shown to 
be significantly lower in intensity of MMP9 relative to the C57 TAC group.  
Fig. 21C. This graph displays MMP9 proteins expression 8 weeks after the aortic banding surgery. Lysates were 
analyzed by western blotting for MMP9 protein expression. The TFAM overexpression TAC group was 
significantly lower in protein expression of MMP9 relative to the C57 TAC group. Both TAC groups were 
significantly increased in MMP9 protein expression when compared to their Sham counterparts.  The bands were 
quantified using densitometry and the data was graphed for an N of 5 using SEM for significance. Values are 














Figure 22. Up-regulated Calpain 1 Expression In HF  
Fig. 22A. These confocal microscopy and ICC images (i-iv) provide intra-cellular visualizations of Calpain1 
within the corresponding experimental groups. Calpain1 is identified in green fluorescence and nuclei are 
identified by blue fluorescence.  
Fig. 22B. This graph exhibits the fluorescent intensity of Calpain1 8-weeks after TAC and was provided by the 
data collected from the Image J software. Each fluorescent intensity corresponds to Calpain1’s presence within the 
specific experimental groups. With respect to Calpain1 fluorescent intensity, the TFAM TAC group was shown to 
be significantly greater in intensity of TFAM relative to the C57 TAC group.  
Fig. 22C. This graph displays Calpain1 proteins expression 8 weeks after the aortic banding surgery. Lysates were 
analyzed by western blotting for Calpain1 protein expression. The TFAM overexpression TAC group was 
significantly greater in protein expression of Calpain1 relative to the C57 TAC group.  The bands were quantified 
using densitometry and the data was graphed for an N of 5 using SEM for significance. Values are expressed as 












Figure 23. Decreased SERCA2a Expression in HF 
Fig. 23A. These confocal microscopy and ICC images (i-iv) provide intra-cellular visualizations of SERCA2a 
within the corresponding experimental groups. SERCA2a is identified in green fluorescence and nuclei are 
identified by blue fluorescence.  
Fig. 23B. This graph exhibits the fluorescent intensity of SERCA2a 8-weeks after TAC and was provided by the 
data collected from the Image J software. Each fluorescent intensity corresponds to SERCA2a’s presence within 
the specific experimental groups. With respect to SERCA2a fluorescent intensity, the TFAM overexpression 
Sham group was significantly greater relative to the C57 Sham group.  Also, the TFAM TAC group was shown to 
be significantly greater in intensity of TFAM relative to the C57 TAC group.  
Fig. 23C. This graph displays SERCA2a proteins expression 8 weeks after the aortic banding surgery. Lysates 
were analyzed by western blotting for SERCA2a protein expression. The TFAM overexpression Sham group was 
significantly greater in protein expression of SERCA2a relative to the C57 Sham group. The TFAM 
overexpression TAC group was significantly greater in protein expression of SERCA2a relative to the C57 TAC 
group. Both TAC groups were significantly decreased in SERCA2a protein expression when compared to their 
Sham counterparts.  The bands were quantified using densitometry and the data was graphed for an N of 5 using 












Figure 24. Interplay of TFAM Over-expression & Cardiac Remodeling Factors 
Fig. 24. The diagram above depicts the figurative comparison of WT control and TFAM overexpression 
cardiomyocytes. It shows the positive conclusion of reduced cardiac remodeling by decreasing MMP9 expression 
and shows TFAM over-expression inhibits NFAT activation. In lack of such inhibition, NFAT would stimulate 
ROS production via NOX 2 & 4 which activates ROS driven MMP9 expression. MMP9 activation is a noted 
pathological marker for cardiac remodeling. Our original hypothesis regarding TFAM activation of SERCA2a and 


















Figure 25. Visual re-evaluation of the Proposed Mechanism of TFAM- Mediated 
Cardiomyocyte Protection 
Fig. 25. This diagram depicts the re-evaluation of the hypothesized mechanism for TFAM’s role in cardiomyocyte 
protection (Fig.3). With respect to the hypothesis, the mechanism for TFAM knockdown was verified but the 
mechanism for TFAM over-expression exhibits two inconsistencies. In the failing cardiomyocyte with TFAM 




















DISCUSSION OF RESULTS 
 
 
We demonstrate for the first time that TFAM maintains an inhibitory 
relationship with the NFAT4-ROS-MMP9 proteolytic pathway in TFAM transgenic 
mice subjected to aortic-banding-induced HF. We also found a mechanistic 
inconsistency in the SERCA2a-Calpain 1 pathway in banded TFAM transgenic mice. 
This finding varied in respect to the literature and our initial proposed mechanism. 
These findings have been expressed in both models of TFAM reduction and over-
expression.  
         We preface this discussion with our findings on TFAM reduction and 
overexpression experimentation. Through in vitro experiments, we observed a 
significant decrease in TFAM protein expression in the TFAM-specific (CRISPR-
cas9) knockdown treatment (Fig.4) and the oxidative stress treatment (Fig.9). 
Additionally, in the in vivo experiments, the aortic-banded WT mouse group 
exhibited a significant decrease in TFAM protein expression (Fig.19). Within this 








Using TFAM reduction, in the in vitro model, we verified the inverse 
relationship between TFAM and the NFAT4-ROS-MMP9 mechanism. NFAT4 
increases NADPH oxidases 2 & 4 to produce ROS in pathological conditions 
(Williams and Gooch 2014). CRISPR knockdown of TFAM increased NFAT4 
expression (Fig.6), increasing cytoplasmic ROS, as found through DHE staining 
(Fig.8). The interaction between TFAM and NFAT4 was first found in the Fujino 
groups work, stating that TFAM mechanistically inhibits NFAT4 transcriptional 
activation (Fujino et al. 2012). 
In HF models in which TFAM is decreased, NFAT4 induces ROS production 
and activates hypertrophic gene expression. NFAT activates pathological cardiac 
hypertrophy, which we confirmed in the WT-TAC models. In TFAM reduction, there 
is a significant increase in heart weight/body weight ratio in comparison to the control 
groups. Furthermore, we observed a significant weight gain, which we deemed a 
result of edema, in the WT-TAC model compared to the control. Other papers have 
found similar results in HF models (Veeraveedu et al. 2017; Ikeda et al. 2015).  
Through histology staining, we also observed cardiac muscle misalignment in 
the WT-TAC model. This observation was supported by H&E staining (Fig.18A), 
which tested for histopathologies. The aortic banding procedure in WT mice resulted 
in myofiber deformation, nuclei misalignment, and inflammation. Additionally, we 
confirmed that TFAM reduction within the WT-TAC group has increased collagen 
intensity, as found through Masson’s Trichrome Staining (Fig.18B). These findings 







In vitro experimentation shows that significantly decreasing TFAM induces 
ROS activated MMP9 (Fig.8C). Exogenous treatment of 127 micromolar H2O2 to HL-
1 cardiomyocytes significantly increased MMP9 protein expression (Fig. 11). Though 
other groups administered 200 micromolar H2O2 to HL-1 cardiomyocytes we 
experienced increased cell death and standardized the treatment. In AV fistula 
volume-overload (VO) heart failure, TFAM overexpression suppressed MMP up 
regulation and limited mitochondrial oxidative stress (Ikeda et al. 2015).  
In TFAM knockdown such as found in the failing heart of control animals 
(Fig.19), excess ROS in the cytoplasm induces MMP9, which we and other groups 
have found increased (Givvimani et al. 2010; Cox et al. 2002). MMPs are 
collagenases and MMP9 excessively degrades collagen but in cardiac remodeling 
collagen turnover is faster than elastin, leading to a stiffening myocardium (Mishra et 
al. 2013). This interplay is a major factor in hypertrophy and heart failure. 
Increased NFAT4 stimulates a cardiac remodeling cascade inducing ROS 
production to increase MMP9, which degrades the extracellular matrix of 
cardiomyocytes. MMP9 is a distinguishing factor in pathological cardiac remodeling 
(Mishra et al. 2013). This observation correlates with known studies showing that 
increased activation of MMPs is observed in TFAM ablation and oxidative stress 
models  (Larsson et al. 1998; Lamparter and Maisch 2000). 
As was expected, TFAM overexpression initiated a chain reaction of 
decreased NFAT and ROS-activated MMP9. In the in vitro and in vivo experiments, 







Hl-1 cardiomyoctes and in the TFAM transgenic mouse model (Fig.4C). In the 
TFAM over-expression model, NFAT4 is reduced (Fig.6). Administration of TFAM 
vector with H2O2 treatment had significantly reduced NFAT4 & MMP9 with respect 
to the H2O2 group alone (Fig. 10 &11).  
 Through TFAM’s inhibition of NFAT, we conclude that aortic banding in 
TFAM-TG mice prevented hypertrophy. In TFAM over-expression, we note a 
significant decrease in NFAT4, which correlates to our visual confirmation of 
reduced hypertrophy in the TFAM-TG banded group. Through analysis of heart 
weight/body weight ratio, we observe a reduction in cardiac hypertrophy with TFAM 
overexpression (Fig.17). Our results are similar to the current literature In AVF 
induced HF models, TFAM overexpression reduced protease activity and cardiac 
hypertrophy (Ikeda et al. 2015). Studies show that TFAM overexpression attenuates 
cardiac dilation and dysfunction in myocardial infarction induced heart failure models 
(Ikeuchi et al. 2005). 
Oxidized proteins are prevalent in heart failure models, TFAM and 
mitochondrial repair enzymes serve to reduce oxidation when overexpressed. 
Overexpression of mitochondrial repair factors in TAC induced HF, decreased left 
ventricular remodeling (Wang et al. 2011). 
In banded TFAM transgenic mice, TFAM overexpression reduced cardiac 
histopathologies. Since NFAT is involved in T-cell modulation, we may be breaching 







potential inflammatory cell signaling pathways from negatively affecting the failing 
myocardium. 
The inhibitory activity of TFAM to reduce NFAT4 pathological hypertrophy 
and ROS-driven MMP9, may delay the myocardium remodeling state, before 
becoming end-stage heart failure. TFAM overexpression protected the aortic banded 
myocardium from cardiac hypertrophy. The LV mass of the WT-TAC was 
significantly heavier than the TFAM-TAC, noting that both were still significantly 
greater than the controls. This suggests that TFAM overexpression reduces the 
hypertrophic and cardiac remodeling process resulting in reduced LV mass (Fig.15).  
         This mechanistic pathway NFAT4-ROS-MMP9 induces cardiac hypertrophy 
and remodeling. Cardiac remodeling includes both intracellular and extracellular 
remodeling factors that induce significant molecular and morphological changes to 
cardiomyocyte structure and function. Remodeling encompasses degradation of the 
extracellular matrix (ECM), pathological hypertrophy, fibrosis, and resultant organ 
dysfunction. This study provides further insight into TFAM’s therapeutic potential in 
TFAM knockdown/overexpression, oxidative stress, and aortic banding induced HF. 
Through this work we have shown that TFAM overexpression has the potential to 
reduce cardiac remodeling factors MMP9 and NFAT4 (Fig. 25). Analysis of 
functional and molecular data, within this work may give insight into the TFAM-
NFAT-ROS-MMP9 pathway. 
         The TFAM-SERCA2a-Calpain 1 pathway reveals a potential avenue for 







interaction with SERCA2a. Following the proposed mechanistic pathway, we found 
that SERCA2a protein expression was as equally significantly reduced in both TFAM 
transgenic and control TAC groups (Fig.23). This finding correlates with reduced 
SERCA2a expression in HF models (Cutler et al. 2009). The downstream effect of 
reduced SERCA2a is increased Ca2+ activated Calpain 1 protein expression was 
significantly increased in the banding animals compared to their controls (Fig.22). 
SERCA2a has a major functional role in physiological Ca2+ regulation and 
cardiomyocyte physiology. The Watanabe group found that exogenous over-
expression of TFAM increased transcriptional activation of SERCA2a (Watanabe et 
al. 2011).  As a result, we hypothesized that TFAM over-expression would heighten 
SERCA2a protein expression, due to an increase in SERCA2a transcriptional 
activation. We presumed that this prominent expression of SERCA2a proteins would 
then drive more cytoplasmic Ca2+ into the SR, reducing Ca2+-activated calpain 
proteases. However, our results, although consistent, did not reflect this mechanism in 
our in vivo or in vitro experiments. In retrospect, we can explain these unexpected 
discoveries as the effect of proteolytic degradation of SERCA2a and inhibition of 
SERCA2a gene transcription. We further analyze the role of epigenetic and 
inflammatory interactions with SERCA2a in HF.  
 In vitro, the TFAM knockdown vector revealed an intensification of 
SERCA2a protein expression when TFAM protein expression was reduced by 50%. 
The TFAM over-expression vector also significantly increased SERCA2a protein 







protein concentration in the failing myocardium. Quantitatively, there were no 
significant differences in SERCA2a protein concentration in the failing hearts of both 
WT and TFAM-TG mice. Upon analysis of these results, we must reevaluate the 
original proposed mechanism behind TFAM’s interaction with SERCA2a.   
 After a thorough review of the literature, we recognized two potential methods 
of SERCA2a decline that possibly caused our results to waver from our hypothesis: 
proteolytic degradation of SERCA2a protein and inhibition of SERCA2a gene 
transcription. Of the many proteases activated by Ca2+, Calpain 1 protease was 
significantly increased within the TAC heart failure model and is unaffected by 
TFAM overexpression (Fig.22). Calpain 1 may degrade the subunits of the SERCA2a 
protein, affect its inhibitors phospholambin and sarcolipin but evidence supporting 
this conjecture is nil and is in need of further exploration. Knocking down TFAM 
increased SERCA2a expression within HL-1 cardiomyocytes. We observe this as an 
immediate compensatory mechanism to reduce free Ca2+ in a stress-induced 
environment. This excess Ca2+ invites proteolytic degratory enzyme Calpain 1, to 
degrade contractile proteins. Interestingly, the excess Ca2+ in the cytoplasm activates 
calpain 1 in the CRISPR Vector group in which SERCA2a expression is significantly 
higher. Therefore, Ca2++-driven calpain 1 levels remain higher than the compensatory 
activity of the SERCA2a pump. Post-translational modifications like degradation 
would result in decreased protein expression of SERCA2a as found in our results. 







mRNA and SERCA2a promoter, these regions may be altered leading to reduced 
SERCA2a protein expression. 
MicroRNAs (miRNA) are small non-coding RNA’s, that function in RNA 
silencing and posttranscriptional regulation of gene expression. MiRNA’s modify 
messenger RNA (mRNA), through cleavage and destabilization. In HF, many 
MiRNAs are dysregulated leading to further cardiomyocyte failure. Of these many 
regulators, miR-25 is significantly expressed in the heart failure myocardium and has 
been shown to inhibit SERCA2a. Mir 25 acts like an SiRNA targeting mRNA for 
degradation instead of transcription. Its inhibitory activity to block SERCA2a, the 
loss of SERCA2a in HF, and its significant upregulation in the HF myocardium led us 
to contemplate whether Mir-25 is inhibiting SERCA2a in the TFAM-TG TAC model 
where our hypothesis does not match our results.  
From a different standpoint; In the presence of a chronic inflammatory state, 
such as found in heart failure, additional mechanistic components are at play. The 
cytoplasmic environmental changes found in heart failure drive adverse mechanistic 
pathways, due to inflammatory cytokine up-regulation (Cocco et al. 2017). We 
recognize that there is a rise in TNF alpha in chronic inflammatory states, as well as 
in tissue samples of HF patients (Valgimigli et al. 2005). According to Huang et al., 
SERCA2a transcription is suppressed via the NFkB-ERK 1,2 pathway (Huang et al. 
2014). This activity was observed in a cardiac hypertrophic state of chronic 
inflammation. We observed that a reduced immune response, the in vitro TFAM 







(Fig. 5). The inflammatory response of the in vivo model may prohibit SERCA2a 
expression at the transcriptional level. Additionally, TFAM regulates interactions 
with TNF alpha in chronic stress environments. 
TFAM is viewed as an endogenous danger signal in damaged cells, due to 
chronic inflammation. Mechanistically, TFAM engages the RAGE factor, (an 
inflammatory response element) initiating the activation of TNF-alpha (Julian et al. 
2013). TNF-alpha, or Tumor Necrosis Factor Alpha, is a cell-signaling cytokine 
involved in inflammation; it is also a mediator of apoptotic cell death (Baxter et al. 
1999). TNF alpha is up-regulated in inflammatory diseases and in heart failure 
(Ogasawara et al. 2017; Valgimigli et al. 2005; Wang, Jia, et al. 2017). Molecular 
evaluation of TNF alpha’s mechanistic regulation over Ca2+ presents TNF alpha’s 
role in activating IP3R and RyR Ca2+ channels, releasing Ca2+ into the cytoplasm 
(Wang, Guo, et al. 2017). 
SERCA2a, a Ca2+ transporter, is functionally inhibited in heart failure; it was 
found that TNF-alpha inhibits the SERCA2a promoter region via methylation (Kao et 
al. 2010). Epigenetic modifications to SERCA2a promoter region reduce its 
transcriptional activity. TNF alpha induces NFkB, which physically binds to the 
SERCA2a gene promoter, blocking its transcription (Tsai et al. 2015). According to 
Huang et al, ERK 1, 2 suppress SERCA2a transcription via NFkB-related 
mechanisms (Huang et al. 2014). This activity was observed in a cardiac hypertrophic 







responsible for reducing SERCA2a in the TFAM transgenic animals with pressure 
overload HF. 
There is a possibility that the inflammatory response involved in HF and the 
induction of extrinsic cell death pathways involving TNF-alpha may be inhibiting 
SERCA2a’s therapeutic potential in the TFAM transgenic model. Inhibition of TNF-
alpha in TFAM transgenic animals may be necessary to proper assessment of TNF-












































SUMMARY, CONCLUSION, & FUTURE DIRECTIONS 
 
 
Cardiovascular diseases are a leading cause of death worldwide. Heart failure 
or the inefficiency of the heart to pump blood, has a high fatality rate five years post 
onset (Mozaffarian et al. 2016). Mitochondrial factors such as TFAM play a vital role 
in inhibiting cardiac remodeling factors, which lead to cardiac hypertrophy and heart 
failure. Heart failure has reduced TFAM expression, increased oxidative stress, Ca2+ 
mishandling, and protease expression leading to cardiomyocyte functional decline 
(Lauritzen et al. 2015). Previous studies involved in TFAM knockdown have resulted 
in reduced mitochondrial biogenesis, dilated cardiomyopathy and neonatal death 
(Larsson et al. 1998).   
TFAM over-expression in in vivo and in vitro studies resulted in 
cellular/functional recovery by reducing oxidative stress and remodeling factors. 
Furthermore, evidence suggests that TFAM plays a vital role in the physiological and 
pathological myocardium. Therefore, mitochondrial-TFAM driven therapeutics are 
under consideration as a promising approach in various diseases. We studied the 
potential treatment capabilities of TFAM by examining its molecular and functional 







We hypothesized that TFAM overexpression reduces pathological cardiac 
remodeling and associated factors in heart failure. In testing this hypothesis, we 
aimed to first analyze the effect of oxidative stress, TFAM CRISPR knockdown and, 
TFAM over-expression on Hl-1 cardiomyocytes. The TFAM knockdown vector 
induced oxidative stress and caused an accumulation of proteolytic and hypertrophic 
remodeling factors. TFAM knockdown triggers a catabolic reaction in which MMPs 
degrade the extracellular matrix of cardiomyocytes. In administering hydrogen 
peroxide to HL-1 cardiomyocytes, we mimicked the robust oxidative stress 
environment of heart failure. Within this objective, we found that TFAM expression 
is significantly reduced in both oxidative stress and TFAM-knockdown vector. 
TFAM reduction significantly increased cardiac remodeling factors such as Calpain 
1, MMP9 and NFAT4. In contrast, TFAM overexpression plays a major role in 
inhibiting the up-regulation of ROS producing factors and transcription factors that 
activate hypertrophic gene regulation. Within this study, we gained support for 
TFAM’s necessary role in cardiomyocyte function.  
In an in vivo model, we hypothesized that TFAM transgenic mice subjected to 
aortic banding would have reduced cardiac hypertrophy post-HF. In this study, we 
found that the aortic banding surgical procedure changed cardiac histopathology and 
function. This change was demonstrated via histology, echocardiography and blood 
pressure which showed that TFAM overexpression reduced functional morphologies 







weight/body weight ratio, that TFAM overexpression reduced aortic banding induced 
hypertrophy.  
The third aim addresses the effect of TFAM overexpression on molecular 
cardiac remodeling factors. Molecular insight into the remodeling cascade shows 
reduced protease and hypertrophic expression in TFAM over-expression models. 
Molecular techniques, including western blotting and IHC, reveal that TFAM over-
expression reduces the NFAT4-ROS-MMP9 cardiac remodeling cascade. However, 
our initial hypothesis, regarding TFAM activation of SERCA2a and reduction of 
Calpain 1, was not confirmed. Many regulatory elements of this potential anomaly 
have been reviewed in the discussion section.  
This study provides mechanistic support of TFAM’s potential to reduce 
mechanistic factors involved in cardiac pathologies. Therefore, TFAM 
overexpression treatment is a possible cardio-therapeutic approach to reducing ROS-
















 Within this section, we discuss the potential of TFAM as a therapeutic in 
diabetic HF, exosomal delivery, natural compounds that increase TFAM, and the 
limitations we face in TFAM-based therapeutic research.   
 
Diabetes & HF 
Diabetes is a devastating, chronic condition that affects millions of 
Americans. As diabetes evolves into a serious public health issue, researchers strain 
to advance the management of diabetic HF. Diabetes significantly increases the risk 
of cardiomyopathies. As we have observed in this work on TFAM’s role in the 
inhibition of cardiac remodeling, considerable molecular changes occur within the 
failing cardiomyocyte of HF control animals. We found evidence of TFAM’s ability 
to mitigate the NFAT-ROS-MMP9 pathway, but TFAM’s cardioprotective potential 
in diabetic HF remains unexplored. Therapeutic mechanistic avenues that reduce left 
ventricular dysfunction in the WT HF models are not as effective in diabetic 
cardiomyopathies. Therefore, we should direct future efforts to the mitigation of 
oxidative stress and hypertrophy in diabetic HF. 
Mitochondrial therapeutic targets such as TFAM are crucial to the reduction 
of oxidative stress. As noted in the literature, hyperglycemia-induced oxidative stress 
is significantly increased in the diabetic myocardium (Dludla et al. 2017; Mandavia et 
al. 2013). Metabolic abnormalities found in diabetes are far more likely to result in 







TFAM over-expression reduces cardiac hypertrophy and fibrosis; therefore, it may 
also reduce hyperglycemia-induced hypertrophy. The Santos group found that 
hyperglycemia diminishes mitochondrial biogenesis and TFAM, suggesting that 
mitochondrial dysregulation in diabetes may be, in part, due to TFAM loss. ROS 
causes molecular dysfunction, creating oxidative damage throughout the diabetic 
myocardium. Clinical methods to reduce oxidative stress are limited, and the world is 
in dire need of exogenous mitochondrial therapy, such as that produced by TFAM 
over-expression. 
  
Exogenous Delivery Mechanisms 
There exists multiple vehicular methods of transporting regulatory elements; 
such transport mechanisms include viruses, bacterial & viral vectors, and 
nanoparticles. The literature thoroughly depicts disadvantages of the various delivery 
methods, particularly the stimulation of immunogenic factors. Exosomes range from 
30-100nm in size and have the potential to be therapeutic game changers in future 
biomedical technology. These nanoparticles are non-immunogenic and transport 
molecules with efficient delivery. Infused within their membranous vessels are 
mRNA, miRNA, siRNA, proteins, and nucleic acids that incite alteration in gene 
expression. Evidence of therapeutic advances using an exosomal delivery system is 
ubiquitous in the literature. As conferred in the Discussion section, Mir-25 is vital to 
the inhibition of the SERCA2a pump. Exosomal delivery of a TFAM over-







WT and diabetic HF models. This method may ameliorate both Ca2+- and ROS-
induced dysfunction. 
 
Natural Methods to Increase TFAM 
Natural methods that exaggerate TFAM, increase mitochondrial function, and 
prevent disease exist in ancient medicinal ingredients. Compounds such as grape seed 
procyanidin B2 (GSPB2), daidzein, humanin, and honokoil increase mitochondrial 
copy number and biogenic function while reducing oxidative stress. GSPB2 inhibited 
glucose-induced apoptosis and suppressed ROS production. Additionally, mRNA 
expressions of NRF-1, TFAM, and mtDNA copy number vastly increased upon 
treatment (Cai et al. 2016). Yoshino et al. describe effects of the dietary substance soy 
isoflavone daidzein on muscle mitochondria. This soy extract directly promotes 
TFAM expression by increasing mitochondrial biogenesis through activation of PGC-
1 alpha(Yoshino et al. 2015). Humanin is a natural mitochondrial peptide that 
significantly increased mtDNA copy number, up-regulated TFAM, activated STAT3, 
and decreased caspase-3 activation and intrinsic apoptosis (Sreekumar et al. 2016). 
Natural remedies have been studied in traditional medicine; as we analyze these 
compounds, we find the mechanistic route to natural therapy. 
Honokoil is a lignan isolated from magnolia tree bark and seed cones. In 
cardiac hypertrophy, honokoil, a known anti-cancer, anti-oxidative, and anti-
inflammatory substance, reduces mitochondrial stress through activation of SIRT-3. 







lessening ROS production. The PGC-1alpha –Sirtuin & TFAM axis plays a major 
role in cardiomyocyte stability (Pillai et al. 2017). FAs observed, honokoil will 
increase TFAM levels, resulting in greater mitochondrial stability and reduced 
hypertrophy. Therefore, the cardioprotective nature of TFAM in diabetic 
cardiomyopathies is a novel possibility and idea. Within the Future Directions of this 
work, we observe that not only biomedical derivations of TFAM, but also natural 
compounds shown to induce TFAM expression, exist and should be tested for 
therapeutic potential. 
 
Limitations of TFAM’s Therapeutic Potential 
It would be immeasurably beneficial to explore and analyze both naturally and 
biomedically derived methods of ameliorating cardiomyopathies through the 
enhancement mitochondrial efficiency. The extent of TFAM’s therapeutic potential is 
also a notable question for any further research in TFAM therapeutics. Limitations of 
TFAM therapeutic potential exist. As we are aware, cancer cells thrive in high 
biogenic environments (Xie et al. 2016). TFAM expression intensifies within a 
variety of cancers, and TFAM is a target of inhibition in cancer research (Mo et al. 
2013). The over-expression of TFAM in a cancer model may cause the cancer to 
metastasize at a faster rate. Additionally, TFAM’s role in protecting and physically 
wrapping around mtDNA would be similar within cancer cells. This may, in fact, 








Mechanistic analysis of TFAM’s function in TFAM over-expression models 
and its potential role in diabetic HF through exosomal delivery and natural 
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● Kunkel GH, Chaturvedi P, Tyagi SC. 2015. “Epigenetic Revival of a Dead Cardiomyocyte 
through mitochondrial interventions” BioMol Concepts (Aug 2015) 
● Chaturvedi P, Kunkel GH, Familsteva A, Tyagi SC. 2016 “Exercise mitigates calpain 1 
induced cardiac dysfunction through PCP-4 in diabetes role” Mol Cell Biochem (In Press) 
 
ABSTRACTS & POSTERS  
● Experimental Biology Conference (2015, 2016) 
● American Physiological Society-Kentucky Chapter Meeting (2015,2016) 
● Research Louisville (2015) 
● SACNAS Conference (2015, 2016) 
● International Academy of Cardiovascular Sciences – Young Investigators Forum (2015) 
● American Physiological Society – Kentucky Chapter Meeting (2015) 
● Baylor College of Medicine “SMART” summer program (2013) 
 
ORAL PRESENTATIONS 
● Invited Speaker: American Physiological Society-KY Chapter Cardiovascular Scientific 
Meeting (2017) 
● Invited Speaker: St. John’s University Biology Department Research Seminar (2015) 
● STJ Biology Honor Society (2013 & 2014) 
● McNair Scholars National Research Conference (2014) 
 
GRANTS 
● Graduate Student SACNAS Travel Scholarship (October 2016) 
● Ruth L. Kirschstein NIH Pre-doctoral Fellowship (July 2016-present) 
● IPIBS Graduate Research Fellowship (August 2014 – June 2016) 
● UofL, School of Med. IPIBS Travel Grant for SACNAS conference (2015) 
● UofL, Dpt. Physiology & Biophysics Travel Grant for EB conference (2015, 2016) 
● Graduate Student Council Travel Grant (2015, 2016) 
● McNair Scholars Stipend for Summer Research (2013) 
● NIH – NHLBI for Baylor College of Medicine Summer Research (2013) 
 
AWARDS & MEMBERSHIP 







● APS-KY Scientific Meeting Awarded “Meritorious Graduate Student Oral Presentation 
Award” at Western Kentucky University (2017) 
● Acknowledged in “Trainee Spotlight” on UofL School of Medicine website 
http://louisville.edu/medicine/grad-postdoc  (June 2016-October 2016)  
● Appointed Graduate Student Officer on UofL School of Medicine Diversity Committee (2016 
– present) 
● Co-founder/Vice President: UofL SACNAS Chapter (Graduate Organization) (2015 – 
present) 
● St. John’s University (STJ) Biology Gold Key Honorable Mention (2014) 
● Member of American Physiological Society (2014 – present) 
● McNair Scholars Research Program (2012 – 2014) 
● Member of American Society of Microbiology (2013) 
● Founder/President of St. John’s U. Chapter of Phi Sigma National Biological Sciences Honor 
Society (2013) 
● Founder: Glen Oaks Volunteer Ambulance Corp. (GOVAC) - STJ Biology Honor Society 
(BHS) Emergency Medical Technician connection program (2013) 
● Founder: Tutoring Affiliation between BHS and Biology & Chemistry departments (2013) 
● Inducted Member of Sigma Pi Sigma National Physics Honor Society (2012) 
● Member of STJ Society of Physics Students (2011) 
● Deans List recipient (2011 – 2014) 
● St. John’s University Academic Scholarship (2010) 
● Vincent O’Connor Leadership Award (2009) 
● St. Francis Preparatory High School Leadership Scholarship (2009 – 2010) 
● St. Francis Preparatory High School Academic Scholarship (2006 – 2010) 
 
SKILLS 
● Radnoti Perfusion: Cardiomyocyte Isolation 
● RNA & Protein Isolation 
● Western Blotting  
● PCR 
● Cell Culture 
● Ultrasound/Echocardiography 
● Surgical Techniques (Mouse & Rat Model) 
● UofL/Kleinert Surgery Institute Microsurgery Certificate (May 2017)  
● Nationally Certified EKG Technician (2011 – 2015) 
● Nationally Certified Phlebotomist (2011 – 2015) 
● New York State Certified Emergency Medical Technician (EMT) (2010 –present) 
● CPR/First Aid Instructor (2011 – 2012) 
 
MENTORED STUDENTS  
● Nicholas Theilen, M.S. (PhD Student) 
● Rohit Nair (MS Student): Graduated August 2016 
● Christopher Kunkel, B.S. (Summer Student – 2017) 
 
EXTRACURRICULAR ACTIVITIES 
● UofL Graduate School (IPIBS) Recruiter (2015-present) 
● Member of Black Knights Men’s Hockey Team (2016-present) 
● EMT – Glen Oaks Volunteer Ambulance Corp. (2011 - 2014) 
● Founded/Managed (BHS) Hayden Nichols Fundraiser (2014) 







● Interviewer for GOVAC – BHS connection program  (2013) 
● Director BHS tutoring (2013) 
● Tutor: General & Organic Chemistry (2013 – 2014) 
● Emergency Center Assistant (Texas Children’s Hospital) (2013) 
● Phlebotomy Teachers Assistant, Queens borough community College (2/2011 – 8/2011)                                                
● CPR & First Aid Instructor, St. Francis Prep. (9/2010 – 5/2011) 
● Volunteer, Little Neck Nursing Home (2007 – 2009) 
 
LITERARY PUBLICATIONS 
● Kunkel, G. H., & Ozuna, H. (2017, January 2). Graduate Students Attend SACNAS 
Conference. UofL Diversity Newsletter. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
